-- Data for Name: sequence_location; Type: TABLE DATA; Schema: cpic; Owner: -
--

COPY cpic.sequence_location (id, version, name, chromosomelocation, genelocation, proteinlocation, genesymbol, dbsnpid, "position") FROM stdin;
6355118	14	A120T	g.117530983G>A	g.70200G>A	p.A120T	CFTR	rs201958172	117530983
6355119	14	I148T	g.117531068T>C	g.70285T>C	p.I148T	CFTR	rs35516286	117531068
6355120	14	M152V	g.117531079A>G	g.70296A>G	p.M152V	CFTR	rs397508721	117531079
6355121	14	R170H	g.117534295G>A	g.73512G>A	p.R170H	CFTR	rs1800079	117534295
6355124	14	G178E	g.117534319G>A	g.73536G>A	p.G178E	CFTR	rs397508748	117534319
777281	105	S549N	g.117587800G>A	g.127017G>A	p.S549N	CFTR	rs121908755	117587800
777305	105	3272-26A->G	g.117611555A>G	g.150772A>G	Intronic	CFTR	rs76151804	117611555
777290	105	F1052V	g.117611595T>G	g.150812T>G	p.F1052V	CFTR	rs150212784	117611595
777291	105	K1060T	g.117611620A>C	g.150837A>C	p.K1060T	CFTR	rs397508513	117611620
777292	105	A1067T	g.117611640G>A	g.150857G>A	p.A1067T	CFTR	rs121909020	117611640
777293	105	G1069R	g.117611646G>A	g.150863G>A	p.G1069R	CFTR	rs200321110	117611646
777294	105	R1070Q	g.117611650G>A	g.150867G>A	p.R1070Q	CFTR	rs78769542	117611650
777296	105	F1074L	g.117611663T>A	g.150880T>A	p.F1074L	CFTR	rs186045772	117611663
777297	105	D1152H	g.117614699G>C	g.153916G>C	p.D1152H	CFTR	rs75541969	117614699
777306	105	3849+10kbC- >T/ Class: V	g.117639961C>T	g.179178C>T	Intronic	CFTR	rs75039782	117639961
777298	105	G1244E	g.117642451G>A	g.181668G>A	p.G1244E	CFTR	rs267606723	117642451
777299	105	S1251N	g.117642472G>A	g.181689G>A	p.S1251N	CFTR	rs74503330	117642472
777300	105	S1255P	g.117642483T>C	g.181700T>C	p.S1255P	CFTR	rs121909041	117642483
777301	105	D1270N	g.117642528G>A	g.181745G>A	p.D1270N	CFTR	rs11971167	117642528
777302	105	G1349D	g.117664770G>A	g.203987G>A	p.G1349D	CFTR	rs193922525	117664770
777389	105	64C>T	g.40991369C>T	g.5071C>T	p.R22C	CYP2B6	rs8192709	40991369
777395	105	12710T>A	g.41004015T>A	g.17717T>A	p.Y62X	CYP2B6	rs281864907	41004015
777396	105	12820G>A	g.41004125G>A	g.17827G>A	p.G99E	CYP2B6	rs36060847	41004125
2899031	58	12828G>A	g.41004133G>A	g.17835G>A	p.A102T	CYP2B6	rs148009906	41004133
2899035	58	13075C>T	g.41004380C>T	g.18082C>T	p.R140W	CYP2B6	rs535039125	41004380
5997181	17	13130G>A	g.41004435G>A	g.18137G>A	p.R158Q	CYP2B6	rs141666881	41004435
2899052	58	21088T>C	g.41012393T>C	g.26095T>C	p.Y354H	CYP2B6	rs754621576	41012393
2899053	58	21089A>G	g.41012394A>G	g.26096A>G	p.Y354C	CYP2B6	rs780991919	41012394
2899064	58	25436G>A	g.41016741G>A	g.30443G>A	p.A464T	CYP2B6	rs117872433	41016741
777418	105	25473G>A	g.41016778G>A	g.30480G>A	p.G476D	CYP2B6	rs564083989	41016778
6234974	15	17839A>G	g.94780544A>G	g.22864A>G	p.N176S	CYP2C19	rs57700608	94780544
948023	97	3531delAGAAATGGAA	g.94942213_94942222del	g.9056_9065del	p.K118fs	CYP2C9	rs1304490498	94942213
5763442	19	3158G>T	g.42127634C>A	g.8177G>T	p.R329L	CYP2D6	rs3915951	42127634
5175088	24	893G>A	g.42129899C>T	g.5912G>A	p.R64H	CYP2D6	rs1415188318	42129899
5175073	24	9_10insA	g.42130783dup	g.5028dup	p.E4fs	CYP2D6	rs1240247139	42130783
828073	104	747A>G	m.747A>G	\N	\N	MT-RNR1	\N	747
828074	104	786G>A	m.786G>A	\N	\N	MT-RNR1	\N	786
896589	99	807A>C; 807A>G	m.807A>C; m.807A>G	\N	\N	MT-RNR1	\N	807
828077	104	827A>G	m.827A>G	\N	\N	MT-RNR1	rs28358569	827
828078	104	839A>G	m.839A>G	\N	\N	MT-RNR1	\N	839
828079	104	896A>G	m.896A>G	\N	\N	MT-RNR1	\N	896
828081	104	951G>A	m.951G>A	\N	\N	MT-RNR1	rs200887992	951
896595	99	960C>del	m.960delC	\N	\N	MT-RNR1	\N	960
896596	99	961T>G	m.961T>G	\N	\N	MT-RNR1	rs3888511	961
1104230	93	961T>del; 961T>del+Cn	m.961delT; m.961delTinsC(n)	\N	\N	MT-RNR1	rs1556422499	961
828086	104	988G>A	m.988G>A	\N	\N	MT-RNR1	\N	988
828087	104	1095T>C	m.1095T>C	\N	\N	MT-RNR1	rs267606618	1095
828088	104	1189T>C	m.1189T>C	\N	\N	MT-RNR1	rs28358571	1189
828089	104	1243T>C	m.1243T>C	\N	\N	MT-RNR1	rs28358572	1243
828090	104	1494C>T	m.1494C>T	\N	\N	MT-RNR1	rs267606619	1494
828091	104	1520T>C	m.1520T>C	\N	\N	MT-RNR1	\N	1520
828092	104	1537C>T	m.1537C>T	\N	\N	MT-RNR1	\N	1537
828093	104	1555A>G	m.1555A>G	\N	\N	MT-RNR1	rs267606617	1555
828094	104	1556C>T	m.1556C>T	\N	\N	MT-RNR1	\N	1556
6481149	13	7A>G	g.18400010A>G	g.13766A>G	p.I3V	NAT2	rs200893121	18400010
7219421	8	67A>C	g.18400070A>C	g.13826A>C	p.T23P	NAT2	rs1464413878	18400070
7219429	8	264G>A	g.18400267G>A	g.14023G>A	p.M88I	NAT2	rs2535896050	18400267
7219444	8	580C>G	g.18400583C>G	g.14339C>G	p.L194V	NAT2	rs774002627	18400583
7219447	8	596T>C	g.18400599T>C	g.14355T>C	p.I199T	NAT2	rs761741098	18400599
7219449	8	613A>T	g.18400616A>T	g.14372A>T	p.M205L	NAT2	rs45607939	18400616
7219453	8	682C>T	g.18400685C>T	g.14441C>T	p.P228S	NAT2	rs150329557	18400685
7219455	8	704T>G	g.18400707T>G	g.14463T>G	p.V235G	NAT2	rs756616433	18400707
779254	105	35305C>A	g.21176879C>A	g.50686C>A	p.P155T	SLCO1B1	rs11045819	21176879
1002601	95	35324G>T	g.21176898G>T	g.50705G>T	splicing defect	SLCO1B1	rs77271279	21176898
1002602	95	37038A>G	g.21178612A>G	g.52419A>G	p.Y173C	SLCO1B1	rs141467543	21178612
779256	105	37041T>C	g.21178615T>C	g.52422T>C	p.V174A	SLCO1B1	rs4149056	21178615
779260	105	37383A>G	g.21178957A>G	g.52764A>G	p.I222V	SLCO1B1	rs79135870	21178957
779261	105	55377A>G	g.21196951A>G	g.70758A>G	p.I245V	SLCO1B1	rs11045852	21196951
1002606	95	55401C>T	g.21196975C>T	g.70782C>T	p.R253X	SLCO1B1	rs183501729	21196975
1002608	95	58970C>G	g.21200544C>G	g.74351C>G	p.P336R	SLCO1B1	rs72559747	21200544
779263	105	59021T>C	g.21200595T>C	g.74402T>C	p.I353T	SLCO1B1	rs55901008	21200595
779265	105	60981C>G	g.21202555C>G	g.76362C>G	p.F400L	SLCO1B1	rs59113707	21202555
779267	105	61090G>A	g.21202664G>A	g.76471G>A	p.G437R	SLCO1B1	rs142965323	21202664
779268	105	64347A>G	g.21205921A>G	g.79728A>G	p.D462G	SLCO1B1	rs72559748	21205921
779269	105	64425G>C	g.21205999G>C	g.79806G>C	p.G488A	SLCO1B1	rs59502379	21205999
1002616	95	64457A>G	g.21206031A>G	g.79838A>G	p.I499V	SLCO1B1	rs74064213	21206031
7850692	3	21_24delACTT	g.18149104_18149107del	g.11037_11040del	p.L8fs	TPMT	\N	18149104
1508723	85	421C>A	g.88131171G>T	g.105152C>A	Q141K	ABCG2	rs2231142	88131171
6355122	14	I175V	g.117534309A>G	g.73526A>G	p.I175V	CFTR	rs397508744	117534309
6355130	14	A234D	g.117535369C>A	g.74586C>A	p.A234D	CFTR	rs769016520	117535369
6355131	14	Q237E	g.117535377C>G	g.74594C>G	p.Q237E	CFTR	rs397508784	117535377
6355132	14	Q237H	g.117535379G>C	g.74596G>C	p.Q237H	CFTR	rs397508785	117535379
6355133	14	F311L	g.117540161T>C	g.79378T>C	p.F311L	CFTR	rs2116683801	117540161
6355134	14	F311del	g.117540161_117540163del	g.79378_79380del	p.F311del	CFTR	\N	117540161
6355135	14	G314E	g.117540171G>A	g.79388G>A	p.G314E	CFTR	rs75763344	117540171
6355136	14	V232D	g.117535363T>A	g.74580T>A	p.V232D	CFTR	rs397508783	117535363
6355137	14	T338I	g.117540243C>T	g.79460C>T	p.T338I	CFTR	rs77409459	117540243
6355138	14	L320V	g.117540188T>G	g.79405T>G	p.L320V	CFTR	rs144476686	117540188
6355139	14	R347H/ Class: IV; R347L	g.117540270G>A; g.117540270G>T	g.79487G>A; g.79487G>T	p.R347H; p.R347L	CFTR	rs77932196	117540270
6355140	14	A349V	g.117540276C>T	g.79493C>T	p.A349V	CFTR	rs121909021	117540276
6355142	14	Q359R	g.117540306A>G	g.79523A>G	p.Q359R	CFTR	rs397508153	117540306
6355144	14	F508C	g.117559594T>C	g.98811T>C	p.F508C	CFTR	rs74571530	117559594
6355150	14	R553Q	g.117587812G>A	g.127029G>A	p.R553Q	CFTR	rs121909044	117587812
6355151	14	V562I	g.117590357G>A	g.129574G>A	p.V562I	CFTR	rs1800097	117590357
6355152	14	G576A	g.117590400G>C	g.129617G>C	p.G576A	CFTR	rs1800098	117590400
6355159	14	I807M	g.117592588A>G	g.131805A>G	p.I807M	CFTR	rs1800103	117592588
6355165	14	H939R	g.117603690A>G	g.142907A>G	p.H939R	CFTR	rs397508440	117603690
6355167	14	M952T	g.117603729T>C	g.142946T>C	p.M952T	CFTR	rs142773283	117603729
6355169	14	L967S	g.117603774T>C	g.142991T>C	p.L967S	CFTR	rs1800110	117603774
777387	105	-82T>C	g.40991224T>C	g.4926T>C	\N	CYP2B6	rs34223104	40991224
777388	105	62A>T	g.40991367A>T	g.5069A>T	p.Q21L	CYP2B6	rs34883432	40991367
777390	105	76A>T	g.40991381A>T	g.5083A>T	p.T26S	CYP2B6	rs33973337	40991381
777391	105	83A>G	g.40991388A>G	g.5090A>G	p.D28G	CYP2B6	rs33980385	40991388
777393	105	86G>C	g.40991391G>C	g.5093G>C	p.R29P	CYP2B6	rs34284776	40991391
777394	105	136A>G	g.40991441A>G	g.5143A>G	p.M46V	CYP2B6	rs35303484	40991441
777397	105	12853G>T	g.41004158G>T	g.17860G>T	p.G110V	CYP2B6	rs186335453	41004158
777398	105	12998T>C	g.41004303T>C	g.18005T>C	p.I114T	CYP2B6	rs139801276	41004303
777399	105	13072A>G	g.41004377A>G	g.18079A>G	p.K139E	CYP2B6	rs12721655	41004377
777400	105	13076G>A	g.41004381G>A	g.18083G>A	p.R140Q	CYP2B6	rs35773040	41004381
777401	105	13101G>T	g.41004406G>T	g.18108G>T	p.E148D	CYP2B6	rs145884402	41004406
777402	105	15614C>G	g.41006919C>G	g.20621C>G	p.P167A	CYP2B6	rs3826711	41006919
777403	105	15618C>T	g.41006923C>T	g.20625C>T	p.T168I	CYP2B6	rs36056539	41006923
777404	105	15631G>T	g.41006936G>T	g.20638G>T	p.Q172H, splice defect	CYP2B6	rs3745274	41006936
2899041	58	15662G>A	g.41006967G>A	g.20669G>A	p.V183I	CYP2B6	rs58871670	41006967
777417	105	15663T>G	g.41006968T>G	g.20670T>G	p.V183G	CYP2B6	rs373489637	41006968
777405	105	15708T>C	g.41007013T>C	g.20715T>C	p.M198T	CYP2B6	rs36079186	41007013
2899044	58	18008A>C	g.41009313A>C	g.23015A>C	p.H247P	CYP2B6	\N	41009313
777406	105	18045C>A	g.41009350C>A	g.23052C>A	p.S259R	CYP2B6	rs45482602	41009350
777407	105	18053A>G	g.41009358A>G	g.23060A>G	p.K262R	CYP2B6	rs2279343	41009358
777408	105	18701G>C	g.41010006G>C	g.23708G>C	p.A279P	CYP2B6	rs139029625	41010006
777409	105	18783C>G	g.41010088C>G	g.23790C>G	p.T306S	CYP2B6	rs34698757	41010088
777420	105	18803C>A	g.41010108C>A	g.23810C>A	p.L313I	CYP2B6	rs193922917	41010108
777410	105	21011T>C	g.41012316T>C	g.26018T>C	p.I328T	CYP2B6	rs28399499	41012316
777411	105	21034C>T	g.41012339C>T	g.26041C>T	p.R336C	CYP2B6	rs34826503	41012339
777412	105	21160C>T	g.41012465C>T	g.26167C>T	p.R378X	CYP2B6	rs34097093	41012465
2899056	58	21166T>C	g.41012471T>C	g.26173T>C	p.Y380H	CYP2B6	rs201500445	41012471
2899057	58	21173T>A	g.41012478T>A	g.26180T>A	p.I382N	CYP2B6	rs200238771	41012478
777413	105	21388T>A	g.41012693T>A	g.26395T>A	p.I391N	CYP2B6	rs35979566	41012693
777421	105	21435G>A	g.41012740G>A	g.26442G>A	p.A407T	CYP2B6	rs193922918	41012740
777414	105	21498C>A	g.41012803C>A	g.26505C>A	p.P428T	CYP2B6	rs35010098	41012803
2899061	58	25347G>A	g.41016652G>A	g.30354G>A	p.R434Q	CYP2B6	rs764288403	41016652
2899062	58	25374G>A	g.41016679G>A	g.30381G>A	p.R443H	CYP2B6	rs374099483	41016679
777415	105	25421A>G	g.41016726A>G	g.30428A>G	p.M459V	CYP2B6	rs3211369	41016726
777516	105	17948G>A	g.94780653G>A	g.22973G>A	p.W212X	CYP2C19	rs4986893	94780653
777517	105	19153C>T	g.94781858C>T	g.24178C>T	p.P227L	CYP2C19	rs6413438	94781858
777518	105	19154G>A	g.94781859G>A	g.24179G>A	splicing defect	CYP2C19	rs4244285	94781859
777519	105	19239G>A	g.94781944G>A	g.24264G>A	p.D256N	CYP2C19	rs375781227	94781944
6235088	15	3558C>T	g.94942240C>T	g.9083C>T	p.S127F	CYP2C9	rs530507053	94942240
6235110	15	10502T>C	g.94949184T>C	g.16027T>C	p.M240T	CYP2C9	rs369745682	94949184
6235120	15	33512A>C	g.94972194A>C	g.39037A>C	p.T304P	CYP2C9	rs546318684	94972194
5997713	17	3199C>G; 3199C>T	g.42127593G>C; g.42127593G>A	g.8218C>G; g.8218C>T	p.R343G; p.R343W	CYP2D6	rs267608295	42127593
5997724	17	2950C>T	g.42127842G>A	g.7969C>T	p.R329C	CYP2D6	rs150216909	42127842
5997750	17	2460G>A	g.42128332C>T	g.7479G>A	p.V229I	CYP2D6	rs993385303	42128332
5997761	17	1916G>A	g.42128876C>T	g.6935G>A	p.G192R	CYP2D6	rs538707090	42128876
5997804	17	912C>A	g.42129880G>T	g.5931C>A	p.S70R	CYP2D6	rs1477736084	42129880
6481150	13	29T>C	g.18400032T>C	g.13788T>C	p.I10T	NAT2	rs72466456	18400032
6481151	13	51C>G	g.18400054C>G	g.13810C>G	p.N17K	NAT2	rs201339185	18400054
6481152	13	58G>T	g.18400061G>T	g.13817G>T	p.D20Y	NAT2	rs532310930	18400061
6481153	13	70T>A	g.18400073T>A	g.13829T>A	p.L24I	NAT2	rs45477599	18400073
6481154	13	121A>T	g.18400124A>T	g.13880A>T	p.N41Y	NAT2	rs149283608	18400124
7219458	8	802A>G	g.18400805A>G	g.14561A>G	p.R268G	NAT2	rs910738034	18400805
779351	105	83A>T	g.18149045T>A	g.11099A>T	p.E28V	TPMT	rs72552742	18149045
777272	105	D110H	g.117530953G>C	g.70170G>C	p.D110H	CFTR	rs113993958	117530953
777283	105	S549R(T>G)	g.117587801T>G	g.127018T>G	p.S549R	CFTR	rs121909005	117587801
6355154	14	S589N	g.117590439G>A	g.129656G>A	p.S589N	CFTR	rs397508300	117590439
6355155	14	R668C	g.117592169C>T	g.131386C>T	p.R668C	CFTR	rs1800100	117592169
6355156	14	S737F	g.117592377C>T	g.131594C>T	p.S737F	CFTR	rs186089140	117592377
6355157	14	V754M	g.117592427G>A	g.131644G>A	p.V754M	CFTR	rs150157202	117592427
6355158	14	R792G	g.117592541C>G	g.131758C>G	p.R792G	CFTR	rs145449046	117592541
6355160	14	E822K	g.117592631G>A	g.131848G>A	p.E822K	CFTR	rs397508378	117592631
6355163	14	R933G	g.117603671A>G	g.142888A>G	p.R933G	CFTR	rs397508436	117603671
6355164	14	D924N	g.117603644G>A	g.142861G>A	p.D924N	CFTR	rs201759207	117603644
6355170	14	G970D	g.117606674G>A	g.145891G>A	p.G970D	CFTR	rs386134230	117606674
6355173	14	Y1014C	g.117610571A>G	g.149788A>G	p.Y1014C	CFTR	rs149279509	117610571
6355174	14	I1027T	g.117610610T>C	g.149827T>C	p.I1027T	CFTR	rs1800112	117610610
6355175	14	Y1032C	g.117610625A>G	g.149842A>G	p.Y1032C	CFTR	rs144055758	117610625
6355178	14	T1053I	g.117611599C>T	g.150816C>T	p.T1053I	CFTR	rs140883683	117611599
6355185	14	I1139V	g.117614660A>G	g.153877A>G	p.I1139V	CFTR	rs397508556	117614660
6355187	14	S1159P	g.117627528T>C	g.166745T>C	p.S1159P	CFTR	rs397508572	117627528
6355188	14	S1159F	g.117627529C>T	g.166746C>T	p.S1159F	CFTR	rs397508573	117627529
6355189	14	R1162L	g.117627538G>T	g.166755G>T	p.R1162L	CFTR	rs1800120	117627538
6355192	14	G1249R(G>A); G1249R(G>C)	g.117642465G>A; g.117642465G>C	g.181682G>A; g.181682G>C	p.G1249R	CFTR	rs397508602	117642465
6355196	14	W1282R	g.117642564T>C	g.181781T>C	p.W1282R	CFTR	rs397508616	117642564
6355197	14	R1283M	g.117642568G>T	g.181785G>T	p.R1283M	CFTR	rs77902683	117642568
6355198	14	Q1291R	g.117642592A>G	g.181809A>G	p.Q1291R	CFTR	rs397508621	117642592
6355199	14	V1293G	g.117652846T>G	g.192063T>G	p.V1293G	CFTR	\N	117652846
6355201	14	H1375P	g.117664848A>C	g.204065A>C	p.H1375P	CFTR	rs397508678	117664848
6355202	14	L1480P	g.117667104T>C	g.206321T>C	p.L1480P	CFTR	rs758818611	117667104
777419	105	25500A>T	g.41016805A>T	g.30507A>T	p.Q485L	CYP2B6	rs2516199080	41016805
777497	105	1A>G	g.94762706A>G	g.5026A>G	p.M1V	CYP2C19	rs28399504	94762706
777498	105	7C>T	g.94762712C>T	g.5032C>T	p.P3S	CYP2C19	rs367543002	94762712
777499	105	10T>C	g.94762715T>C	g.5035T>C	p.F4L	CYP2C19	rs367543003	94762715
777500	105	50T>C	g.94762755T>C	g.5075T>C	p.L17P	CYP2C19	rs55752064	94762755
777501	105	55A>C	g.94762760A>C	g.5080A>C	p.I19L	CYP2C19	rs17882687	94762760
777502	105	83A>T	g.94762788A>T	g.5108A>T	p.K28I	CYP2C19	rs1564656981	94762788
777503	105	151A>G	g.94762856A>G	g.5176A>G	p.S51G	CYP2C19	rs1564657013	94762856
777504	105	12401C>T	g.94775106C>T	g.17426C>T	p.R73C	CYP2C19	rs145328984	94775106
777505	105	12416C>T	g.94775121C>T	g.17441C>T	p.H78Y	CYP2C19	rs1564660997	94775121
777506	105	12455G>C	g.94775160G>C	g.17480G>C	p.G91R	CYP2C19	rs118203756	94775160
777507	105	12480A>G	g.94775185A>G	g.17505A>G	p.H99R	CYP2C19	rs1288601658	94775185
777508	105	12662A>G	g.94775367A>G	g.17687A>G	splicing defect	CYP2C19	rs12769205	94775367
777509	105	12711T>C	g.94775416T>C	g.17736T>C	p.W120R	CYP2C19	rs41291556	94775416
777513	105	12802G>A	g.94775507G>A	g.17827G>A	p.R150H	CYP2C19	rs58973490	94775507
777514	105	17869G>C	g.94780574G>C	g.22894G>C	p.R186P	CYP2C19	rs140278421	94780574
777515	105	17874G>A	g.94780579G>A	g.22899G>A	p.D188N	CYP2C19	rs370803989	94780579
777521	105	80156G>A	g.94842861G>A	g.85181G>A	p.R329H	CYP2C19	rs138142612	94842861
777522	105	80161A>G	g.94842866A>G	g.85186A>G	p.I331V	CYP2C19	rs3758581	94842866
777523	105	80174G>A	g.94842879G>A	g.85199G>A	p.R335Q	CYP2C19	rs118203757	94842879
777524	105	80290G>A	g.94842995G>A	g.85315G>A	p.V374I	CYP2C19	rs113934938	94842995
777525	105	87290C>T	g.94849995C>T	g.92315C>T	p.R410C	CYP2C19	rs17879685	94849995
777526	105	90033C>T	g.94852738C>T	g.95058C>T	p.R433W	CYP2C19	rs56337013	94852738
777527	105	90060C>T	g.94852765C>T	g.95085C>T	p.R442C	CYP2C19	rs192154563	94852765
777528	105	90080C>G	g.94852785C>G	g.95105C>G	p.F448L	CYP2C19	rs118203759	94852785
777647	105	42548C>A	g.94981230C>A	g.48073C>A	p.P337T	CYP2C9	rs1274535931	94981230
6235852	15	18726C>G	g.15878886G>C	g.24189C>G	p.A483G	CYP4F2	rs3952537	15878886
6235855	15	18199C>T	g.15879413G>A	g.23662C>T	p.R444C	CYP4F2	rs142113670	15879413
6235860	15	5233C>T	g.15892379G>A	g.10696C>T	p.T152M	CYP4F2	rs200629062	15892379
6235861	15	5214C>T	g.15892398G>A	g.10677C>T	p.R146C	CYP4F2	rs556151888	15892398
6235863	15	2086G>A	g.15895526C>T	g.7549G>A	p.R108Q	CYP4F2	rs148396222	15895526
6235865	15	2061A>G	g.15895551T>C	g.7524A>G	p.S100G	CYP4F2	rs150579280	15895551
778315	105	c.2657G>A	g.97098598C>T	g.827462G>A	p.R886H	DPYD	rs1801267	97098598
778508	105	c.179T>C	g.154536025A>G	g.16548T>C	p.L60P	G6PD	\N	154536025
2406797	67	c.383T>G;c.383T>C	g.154535270A>C;g.154535270A>G	g.17303T>G;g.17303T>C	p.L128R;p.L128P	G6PD	rs78365220	154535270
2406845	67	c.835A>G;c.835A>T	g.154533605T>C;g.154533605T>A	g.18968A>G;g.18968A>T	p.T279A;p.T279S	G6PD	\N	154533605
6481155	13	152G>T	g.18400155G>T	g.13911G>T	p.G51V	NAT2	rs72466457	18400155
6481156	13	190C>T	g.18400193C>T	g.13949C>T	p.R64W	NAT2	rs1805158	18400193
6481157	13	191G>A	g.18400194G>A	g.13950G>A	p.R64Q	NAT2	rs1801279	18400194
6481158	13	203G>A	g.18400206G>A	g.13962G>A	p.C68Y	NAT2	rs72466458	18400206
7219460	8	823T>A	g.18400826T>A	g.14582T>A	p.L275M	NAT2	rs148566670	18400826
7219462	8	845A>G	g.18400848A>G	g.14604A>G	p.K282R	NAT2	rs56054745	18400848
779253	105	35294A>G	g.21176868A>G	g.50675A>G	p.N151S	SLCO1B1	rs2306282	21176868
6237858	15	37079C>G	g.21178653C>G	g.52460C>G	p.P187A	SLCO1B1	rs200331427	21178653
6237859	15	37352A>G	g.21178926A>G	g.52733A>G	p.I211M	SLCO1B1	rs201722521	21178926
6237875	15	83266G>A	g.21224840G>A	g.98647G>A	splicing defect	SLCO1B1	rs200994482	21224840
779274	105	97584C>T	g.21239158C>T	g.112965C>T	p.S682F	SLCO1B1	rs140790673	21239158
777603	105	55C>A	g.94938737C>A	g.5580C>A	p.L19I	CYP2C9	rs67807361	94938737
777604	105	89C>T	g.94938771C>T	g.5614C>T	p.P30L	CYP2C9	rs142240658	94938771
777607	105	3215G>C	g.94941897G>C	g.8740G>C	p.G70R	CYP2C9	rs371055887	94941897
777615	105	3548C>T	g.94942230C>T	g.9073C>T	p.R124W	CYP2C9	rs767576260	94942230
777622	105	3608C>T	g.94942290C>T	g.9133C>T	p.R144C	CYP2C9	rs1799853	94942290
777623	105	3609G>A	g.94942291G>A	g.9134G>A	p.R144H	CYP2C9	rs141489852	94942291
777628	105	9187A>G	g.94947869A>G	g.14712A>G	p.D191G	CYP2C9	rs2492587526	94947869
777630	105	9235T>C	g.94947917T>C	g.14760T>C	p.I207T	CYP2C9	rs1326630788	94947917
1985225	75	9257G>T	g.94947939G>T	g.14782G>T	p.Q214H	CYP2C9	rs370100007	94947939
777632	105	10447A>G	g.94949129A>G	g.15972A>G	p.I222V	CYP2C9	\N	94949129
1932796	76	10481delT	g.94949163del	g.16006del	p.L233fs	CYP2C9	\N	94949163
777634	105	10535A>G	g.94949217A>G	g.16060A>G	p.H251R	CYP2C9	rs2256871	94949217
777635	105	10598A>G	g.94949280A>G	g.16123A>G	p.E272G	CYP2C9	rs9332130	94949280
948046	97	10601delA	g.94949283del	g.16126del	p.K273fs	CYP2C9	rs9332131	94949283
777639	105	33452A>G	g.94972134A>G	g.38977A>G	p.I284V	CYP2C9	rs2492634549	94972134
777641	105	33498C>G	g.94972180C>G	g.39023C>G	p.T299R	CYP2C9	rs988617574	94972180
777661	105	50198G>T	g.94988880G>T	g.55723G>T	p.G442V	CYP2C9	rs2492662839	94988880
777667	105	50341G>T	g.94989023G>T	g.55866G>T	p.V490F	CYP2C9	rs868182778	94989023
777923	105	4132A>G	g.42126660T>C	g.9151A>G	p.T470A	CYP2D6	rs1135835	42126660
3307484	50	3261_3262insTG	g.42127532_42127533dup	g.8279_8280dup	p.Q364fs	CYP2D6	rs72549346	42127532
1103041	93	2590delCTGA	g.42128199TCAG[1]	g.7605CTGA[1]	p.T272fs	CYP2D6	rs72549351	42128199
777856	105	1888_1889insTA	g.42128903_42128904insTA	g.6907_6908insTA	p.S183X	CYP2D6	\N	42128903
777832	105	1022C>A; 1022C>T	g.42129770G>T; g.42129770G>A	g.6041C>A; g.6041C>T	p.T107N; p.T107I	CYP2D6	rs28371706	42129770
778312	105	c.2623A>C	g.97098632T>G	g.827428A>C	p.K875Q	DPYD	rs201035051	97098632
778313	105	c.2639G>T	g.97098616C>A	g.827444G>T	p.G880V	DPYD	rs55674432	97098616
778314	105	c.2656C>T	g.97098599G>A	g.827461C>T	p.R886C	DPYD	rs147545709	97098599
778324	105	c.3049G>A	g.97079005C>T	g.847055G>A	p.V1017I	DPYD	rs140114515	97079005
778325	105	c.3061G>C	g.97078993C>G	g.847067G>C	p.V1021L	DPYD	rs148799944	97078993
778595	105	c.1000_1002delACC	g.154532991_154532993delGGT	g.19580_19582delACC	p.T334del	G6PD	\N	154532991
778596	105	c.1003G>A	g.154532990C>T	g.19583G>A	p.A335T	G6PD	rs5030869	154532990
778597	105	c.1004C>A	g.154532989G>T	g.19584C>A	p.A335D	G6PD	\N	154532989
6481160	13	248G>C	g.18400251G>C	g.14007G>C	p.G83A	NAT2	rs561124342	18400251
6481162	13	321C>A	g.18400324C>A	g.14080C>A	p.H107Q	NAT2	rs549917500	18400324
6481163	13	341T>C	g.18400344T>C	g.14100T>C	p.I114T	NAT2	rs1801280	18400344
6481164	13	346G>A	g.18400349G>A	g.14105G>A	p.G116S	NAT2	rs183409091	18400349
6481165	13	364G>A	g.18400367G>A	g.14123G>A	p.D122N	NAT2	rs4986996	18400367
6481166	13	403C>G	g.18400406C>G	g.14162C>G	p.L135V	NAT2	rs12720065	18400406
6481168	13	458C>T	g.18400461C>T	g.14217C>T	p.T153I	NAT2	rs72466460	18400461
6481169	13	472A>C	g.18400475A>C	g.14231A>C	p.I158L	NAT2	rs139351995	18400475
6481170	13	475T>A	g.18400478T>A	g.14234T>A	p.W159R	NAT2	rs537007806	18400478
6481172	13	491T>C	g.18400494T>C	g.14250T>C	p.I164T	NAT2	rs139512288	18400494
6481173	13	499G>A	g.18400502G>A	g.14258G>A	p.E167K	NAT2	rs72554617	18400502
6481174	13	506A>G	g.18400509A>G	g.14265A>G	p.Y169C	NAT2	rs200585149	18400509
6481175	13	518A>G	g.18400521A>G	g.14277A>G	p.K173R	NAT2	rs369500066	18400521
6481176	13	536A>G	g.18400539A>G	g.14295A>G	p.H179R	NAT2	rs572750517	18400539
6481177	13	578C>T	g.18400581C>T	g.14337C>T	p.T193M	NAT2	rs79050330	18400581
6481178	13	589C>T	g.18400592C>T	g.14348C>T	p.R197X	NAT2	rs375746304	18400592
6481179	13	590G>A	g.18400593G>A	g.14349G>A	p.R197Q	NAT2	rs1799930	18400593
6481180	13	609G>T	g.18400612G>T	g.14368G>T	p.E203D	NAT2	rs45618543	18400612
6481181	13	622T>C	g.18400625T>C	g.14381T>C	p.Y208H	NAT2	rs56387565	18400625
6481182	13	638C>T	g.18400641C>T	g.14397C>T	p.P213L	NAT2	rs138707146	18400641
6481183	13	650T>A	g.18400653T>A	g.14409T>A	p.F217Y	NAT2	rs568110818	18400653
6481184	13	683C>T	g.18400686C>T	g.14442C>T	p.P228L	NAT2	rs45518335	18400686
779045	105	2T>C	g.48037748T>C	g.5182T>C	p.M1T	NUDT15	rs769369441	48037748
779046	105	3G>C	g.48037749G>C	g.5183G>C	p.M1I	NUDT15	\N	48037749
779048	105	52G>A	g.48037798G>A	g.5232G>A	p.V18I	NUDT15	rs186364861	48037798
779050	105	80_81insCGGG	g.48037826_48037827insCGGG	g.5260_5261insCGGG	p.C28fs	NUDT15	rs777311140	48037826
779051	105	88C>T	g.48037834C>T	g.5268C>T	p.L30F	NUDT15	rs1202487323	48037834
779052	105	101G>C	g.48037847G>C	g.5281G>C	p.R34T	NUDT15	rs766023281	48037847
779053	105	103A>G	g.48037849A>G	g.5283A>G	p.K35E	NUDT15	\N	48037849
779054	105	139G>A	g.48037885G>A	g.5319G>A	p.G47R	NUDT15	rs1950545307	48037885
779055	105	156C>G	g.48037902C>G	g.5336C>G	p.F52L	NUDT15	rs149436418	48037902
949537	97	3236delA	g.48040982del	g.8416del	p.N74fs	NUDT15	rs1457579126	48040982
949538	97	3358_3359insG	g.48041104dup	g.8538dup	p.E115fs	NUDT15	rs761191455	48041104
779058	105	3367G>T	g.48041113G>T	g.8547G>T	p.E118X	NUDT15	rs1368252918	48041113
779059	105	7944C>G	g.48045690C>G	g.13124C>G	p.P129R	NUDT15	rs768324690	48045690
5881932	18	7968G>C	g.48045714G>C	g.13148G>C	p.G137A	NUDT15	rs1185228044	48045714
779060	105	7973C>T	g.48045719C>T	g.13153C>T	p.R139C	NUDT15	rs116855232	48045719
1002617	95	80781C>T	g.21222355C>T	g.96162C>T	p.R580X	SLCO1B1	rs71581941	21222355
779270	105	97468A>C	g.21239042A>C	g.112849A>C	p.L643F	SLCO1B1	rs34671512	21239042
779271	105	97503A>G	g.21239077A>G	g.112884A>G	p.D655G	SLCO1B1	rs56199088	21239077
779272	105	97539A>G	g.21239113A>G	g.112920A>G	p.E667G	SLCO1B1	rs55737008	21239113
779273	105	97571C>T	g.21239145C>T	g.112952C>T	p.H678Y	SLCO1B1	rs200995543	21239145
1932756	76	37T>G	g.94938719T>G	g.5562T>G	p.C13G	CYP2C9	\N	94938719
1932759	76	106C>T	g.94938788C>T	g.5631C>T	p.L36F	CYP2C9	\N	94938788
1932760	76	118G>A	g.94938800G>A	g.5643G>A	p.G40R	CYP2C9	rs1364419386	94938800
777605	105	121A>G	g.94938803A>G	g.5646A>G	p.N41D	CYP2C9	rs2031308986	94938803
777606	105	146A>G	g.94938828A>G	g.5671A>G	p.D49G	CYP2C9	rs564813580	94938828
777608	105	3233G>A	g.94941915G>A	g.8758G>A	p.V76M	CYP2C9	rs1216169538	94941915
777609	105	3276T>C	g.94941958T>C	g.8801T>C	p.L90P	CYP2C9	rs72558187	94941958
1932766	76	3293G>A	g.94941975G>A	g.8818G>A	p.G96R	CYP2C9	rs2493006942	94941975
777610	105	3294G>C	g.94941976G>C	g.8819G>C	p.G96A	CYP2C9	rs761033063	94941976
777612	105	3336T>C	g.94942018T>C	g.8861T>C	p.F110S	CYP2C9	\N	94942018
777614	105	3534A>G	g.94942216A>G	g.9059A>G	p.K119R	CYP2C9	rs774607211	94942216
777616	105	3549G>A	g.94942231G>A	g.9074G>A	p.R124Q	CYP2C9	rs12414460	94942231
777617	105	3551C>T	g.94942233C>T	g.9076C>T	p.R125C	CYP2C9	rs375805362	94942233
1932776	76	3561T>G	g.94942243T>G	g.9086T>G	p.L128R	CYP2C9	rs1375956433	94942243
777620	105	3572C>T	g.94942254C>T	g.9097C>T	p.R132W	CYP2C9	rs199523631	94942254
777621	105	3573G>A	g.94942255G>A	g.9098G>A	p.R132Q	CYP2C9	rs200183364	94942255
777624	105	3623G>A	g.94942305G>A	g.9148G>A	p.A149T	CYP2C9	rs754487195	94942305
1406126	87	3624C>T	g.94942306C>T	g.9149C>T	p.A149V	CYP2C9	rs1289704600	94942306
1406127	87	3626C>T	g.94942308C>T	g.9151C>T	p.R150C	CYP2C9	rs17847037	94942308
777625	105	3627G>A; 3627G>T	g.94942309G>A; g.94942309G>T	g.9152G>A; g.9152G>T	p.R150H; p.R150L	CYP2C9	rs7900194	94942309
777626	105	9100C>A	g.94947782C>A	g.14625C>A	p.S162X	CYP2C9	rs72558190	94947782
777627	105	9103C>T	g.94947785C>T	g.14628C>T	p.P163L	CYP2C9	rs774550549	94947785
777629	105	9225A>C	g.94947907A>C	g.14750A>C	p.N204H	CYP2C9	\N	94947907
777631	105	9256A>T	g.94947938A>T	g.14781A>T	p.Q214L	CYP2C9	rs2031531005	94947938
777633	105	10462C>T	g.94949144C>T	g.15987C>T	p.P227S	CYP2C9	rs2492591692	94949144
1932795	76	10463C>T	g.94949145C>T	g.15988C>T	p.P227L	CYP2C9	rs772782449	94949145
777637	105	33437C>A	g.94972119C>A	g.38962C>A	p.P279T	CYP2C9	rs182132442	94972119
777638	105	33441C>G	g.94972123C>G	g.38966C>G	p.S280C	CYP2C9	\N	94972123
777640	105	33497A>G	g.94972179A>G	g.39022A>G	p.T299A	CYP2C9	rs72558192	94972179
1932805	76	33501A>T	g.94972183A>T	g.39026A>T	p.E300V	CYP2C9	\N	94972183
777642	105	33551C>T	g.94972233C>T	g.39076C>T	p.P317S	CYP2C9	rs1237225311	94972233
777658	105	47391A>C	g.94986073A>C	g.52916A>C	p.D397A	CYP2C9	rs72558193	94986073
1406163	87	47454A>C	g.94986136A>C	g.52979A>C	p.N418T	CYP2C9	rs1254213342	94986136
1932825	76	47492G>C	g.94986174G>C	g.53017G>C	p.G431R	CYP2C9	rs1441296358	94986174
777664	105	50273T>C	g.94988955T>C	g.55798T>C	p.L467P	CYP2C9	rs767284820	94988955
777665	105	50302G>A	g.94988984G>A	g.55827G>A	p.A477T	CYP2C9	rs781583846	94988984
777666	105	50338C>T	g.94989020C>T	g.55863C>T	p.P489S	CYP2C9	rs9332239	94989020
777925	105	4145G>A	g.42126647C>T	g.9164G>A	p.R474Q	CYP2D6	rs141756339	42126647
778606	105	c.1084_1101delCTGAACGAGCGCAAGGCC	g.154532753_154532770delGGCCTTGCGCTCGTTCAG	g.19803_19820delCTGAACGAGCGCAAGGCC	p.L362_A367del	G6PD	\N	154532753
2406876	67	c.1089C>G;c.1089C>A	g.154532765G>C;g.154532765G>T	g.19808C>G;g.19808C>A	p.N363K;N363K	G6PD	rs137852329	154532765
6481185	13	766A>G	g.18400769A>G	g.14525A>G	p.K256E	NAT2	rs55700793	18400769
6481186	13	796G>A	g.18400799G>A	g.14555G>A	p.V266M	NAT2	rs539346244	18400799
6481187	13	803G>A	g.18400806G>A	g.14562G>A	p.R268K	NAT2	rs1208	18400806
6481188	13	838G>A	g.18400841G>A	g.14597G>A	p.V280M	NAT2	rs56393504	18400841
6481189	13	857G>A	g.18400860G>A	g.14616G>A	p.G286E	NAT2	rs1799931	18400860
3684992	43	c.97A>G	g.38440796A>G	g.12097A>G	p.K33E	RYR1	rs193922746	38440796
779104	105	c.103T>C	g.38440802T>C	g.12103T>C	p.C35R	RYR1	rs193922747	38440802
3684994	43	c.119G>C	g.38440818G>C	g.12119G>C	p.G40A	RYR1	\N	38440818
779105	105	c.130C>T	g.38440829C>T	g.12130C>T	p.R44C	RYR1	rs193922748	38440829
3685000	43	c.212C>A	g.38442395C>A	g.13696C>A	p.S71Y	RYR1	rs118192113	38442395
3685001	43	c.251C>T	g.38442434C>T	g.13735C>T	p.T84M	RYR1	rs186983396	38442434
3685002	43	c.418G>A	g.38443790G>A	g.15091G>A	p.A140T	RYR1	rs142474192	38443790
3685003	43	c.455C>A	g.38444179C>A	g.15480C>A	p.A152D	RYR1	\N	38444179
3685004	43	c.463C>A	g.38444187C>A	g.15488C>A	p.Q155K	RYR1	rs193922750	38444187
3685005	43	c.467G>A	g.38444191G>A	g.15492G>A	p.R156K	RYR1	rs193922751	38444191
3685009	43	c.493G>A	g.38444217G>A	g.15518G>A	p.G165R	RYR1	rs193922754	38444217
3685010	43	c.496G>A	g.38444220G>A	g.15521G>A	p.D166N	RYR1	rs193922755	38444220
3685011	43	c.497A>G	g.38444221A>G	g.15522A>G	p.D166G	RYR1	rs193922756	38444221
3685012	43	c.526G>A	g.38444250G>A	g.15551G>A	p.E176K	RYR1	rs761616815	38444250
779109	105	c.982C>T	g.38448673C>T	g.19974C>T	p.R328W	RYR1	rs193922762	38448673
3685134	43	c.7090T>G	g.38499697T>G	g.70998T>G	p.F2364V	RYR1	rs193922805	38499697
3685158	43	c.7487C>T	g.38500863C>T	g.72164C>T	p.P2496L	RYR1	rs193922817	38500863
779137	105	c.7522C>T; c.7522C>G	g.38500898C>T; g.38500898C>G	g.72199C>T; g.72199C>G	p.R2508C; p.R2508G	RYR1	rs118192178	38500898
779138	105	c.7523G>A	g.38500899G>A	g.72200G>A	p.R2508H	RYR1	rs193922818	38500899
3685161	43	c.7528T>C	g.38500904T>C	g.72205T>C	p.Y2510H	RYR1	rs193922819	38500904
3685164	43	c.7777C>G	g.38502669C>G	g.73970C>G	p.R2593G	RYR1	\N	38502669
3685165	43	c.7778G>A	g.38502670G>A	g.73971G>A	p.R2593H	RYR1	rs751180702	38502670
3685166	43	c.7787C>T	g.38502679C>T	g.73980C>T	p.T2596I	RYR1	rs193922824	38502679
3685167	43	c.7816T>A	g.38502708T>A	g.74009T>A	p.C2606S	RYR1	rs748575133	38502708
3685170	43	c.8026C>T	g.38504319C>T	g.75620C>T	p.R2676W	RYR1	rs193922826	38504319
3685185	43	c.9152G>A	g.38511590G>A	g.82891G>A	p.R3051H	RYR1	rs147303895	38511590
3685297	43	c.14817C>A	g.38585951C>A	g.157252C>A	p.D4939E	RYR1	rs193922895	38585951
777644	105	42519T>C	g.94981201T>C	g.48044T>C	p.I327T	CYP2C9	rs57505750	94981201
777645	105	42542C>T	g.94981224C>T	g.48067C>T	p.R335W	CYP2C9	rs28371685	94981224
777646	105	42543G>A	g.94981225G>A	g.48068G>A	p.R335Q	CYP2C9	rs367826293	94981225
777656	105	42689G>A	g.94981371G>A	g.48214G>A	splicing defect	CYP2C9	rs542577750	94981371
777659	105	50170C>T	g.94988852C>T	g.55695C>T	p.R433W	CYP2C9	rs776908257	94988852
777660	105	50173A>T	g.94988855A>T	g.55698A>T	p.I434F	CYP2C9	rs2492662738	94988855
777662	105	50235G>C	g.94988917G>C	g.55760G>C	p.Q454H	CYP2C9	rs769942899	94988917
777663	105	50243A>G	g.94988925A>G	g.55768A>G	p.N457S	CYP2C9	rs202201137	94988925
2090875	73	1985G>A	g.42128807C>T	g.7004G>A	p.E215K	CYP2D6	rs567606867	42128807
1609173	83	1979C>T	g.42128813G>A	g.6998C>T	\N	CYP2D6	rs150163869	42128813
1103027	93	1977_1978insG	g.42128817dup	g.6996dup	p.L213fs	CYP2D6	rs72549354	42128817
2676642	62	1928G>A	g.42128864C>T	g.6947G>A	p.E196K	CYP2D6	rs755518310	42128864
2676638	62	1866A>G	g.42128926T>C	g.6885A>G	p.N175S	CYP2D6	rs1459127426	42128926
2676637	62	1860G>A	g.42128932C>T	g.6879G>A	p.R173H	CYP2D6	rs556882139	42128932
777854	105	1847G>A	g.42128945C>T	g.6866G>A	splicing defect	CYP2D6	rs3892097	42128945
3619338	44	1759G>T, 1759G>A	g.42129033C>A; g.42129033C>T	g.6778G>T; g.6778G>A	p.G169X; p.G169R	CYP2D6	rs5030865	42129033
777852	105	1756T>G	g.42129036A>C	g.6775T>G	p.S168A	CYP2D6	rs1135826	42129036
777851	105	1755C>A	g.42129037G>T	g.6774C>A	p.H167Q	CYP2D6	rs1135825	42129037
777850	105	1750A>G	g.42129042T>C	g.6769A>G	p.N166D	CYP2D6	rs1135824	42129042
2090861	73	1748C>T	g.42129044G>A	g.6767C>T	p.A165V	CYP2D6	rs201006451	42129044
777849	105	1736G>C	g.42129056C>G	g.6755G>C	p.C161S	CYP2D6	rs774943042	42129056
777847	105	1717G>A	g.42129075C>T	g.6736G>A	p.E155K	CYP2D6	rs28371710	42129075
1103013	93	1708delT	g.42129084del	g.6727del	p.W152fs	CYP2D6	rs5030655	42129084
777845	105	1705C>G	g.42129087G>C	g.6724C>G	p.Q151E	CYP2D6	rs78482768	42129087
777844	105	1694A>G	g.42129098T>C	g.6713A>G	p.K147R	CYP2D6	rs569229126	42129098
777843	105	1679T>C	g.42129113A>G	g.6698T>C	p.L142S	CYP2D6	rs375135093	42129113
777842	105	1662G>C	g.42129130C>G	g.6681G>C	\N	CYP2D6	rs1058164	42129130
777841	105	1660G>A	g.42129132C>T	g.6679G>A	p.V136M	CYP2D6	rs61736512	42129132
777840	105	1658C>T	g.42129134G>A	g.6677C>T	p.S135F	CYP2D6	rs781457579	42129134
777839	105	1637G>A	g.42129155C>T	g.6656G>A	p.W128X	CYP2D6	rs1180015037	42129155
2090849	73	1636T>C	g.42129156A>G	g.6655T>C	p.W128R	CYP2D6	rs376636053	42129156
777838	105	1626T>G	g.42129166A>C	g.6645T>G	p.Y124X	CYP2D6	rs766391487	42129166
777837	105	1618G>T	g.42129174C>A	g.6637G>T	p.A122S	CYP2D6	rs1135823	42129174
777836	105	1612T>A	g.42129180A>T	g.6631T>A	p.F120I	CYP2D6	rs1135822	42129180
2090845	73	1609G>A; 1609G>T	g.42129183C>T; g.42129183C>A	g.6628G>A; g.6628G>T	p.V119M; p.V119L	CYP2D6	rs374616348	42129183
2676613	62	1052A>G	g.42129740T>C	g.6071A>G	p.Q117R	CYP2D6	\N	42129740
3318096	49	1039G>C	g.42129753C>G	g.6058G>C	p.G113R	CYP2D6	rs563185985	42129753
777834	105	1033G>A	g.42129759C>T	g.6052G>A	p.G111S	CYP2D6	rs535642512	42129759
777833	105	1027A>G	g.42129765T>C	g.6046A>G	p.I109V	CYP2D6	rs78459009	42129765
777831	105	1021A>T	g.42129771T>A	g.6040A>T	p.T107S	CYP2D6	rs74802369	42129771
777830	105	1013T>C	g.42129779A>G	g.6032T>C	p.V104A	CYP2D6	rs76187628	42129779
777829	105	1012G>A	g.42129780C>T	g.6031G>A	p.V104M	CYP2D6	rs267608308	42129780
1102995	93	993C>G	g.42129799G>C	g.6012C>G	p.D97E	CYP2D6	rs76802407	42129799
777828	105	983A>G	g.42129809T>C	g.6002A>G	p.H94R	CYP2D6	rs28371704	42129809
777827	105	973C>A	g.42129819G>T	g.5992C>A	p.L91M	CYP2D6	rs28371703	42129819
777826	105	971C>T	g.42129821G>A	g.5990C>T	p.A90V	CYP2D6	rs267608309	42129821
777825	105	965G>C	g.42129827C>G	g.5984G>C	p.R88P	CYP2D6	rs267608276	42129827
777824	105	956C>T	g.42129836G>A	g.5975C>T	p.A85V	CYP2D6	rs267608310	42129836
777823	105	905T>G	g.42129887A>C	g.5924T>G	p.V68G	CYP2D6	rs1456026511	42129887
777821	105	882G>C	g.42129910C>G	g.5901G>C	splicing defect	CYP2D6	rs201377835	42129910
2090829	73	154C>T	g.42130638G>A	g.5173C>T	p.Q52X	CYP2D6	rs536109057	42130638
1102986	93	137_138insT	g.42130655dup	g.5156dup	p.L47fs	CYP2D6	rs774671100	42130655
777819	105	125G>A	g.42130667C>T	g.5144G>A	p.G42E	CYP2D6	rs118203758	42130667
777818	105	124G>A	g.42130668C>T	g.5143G>A	p.G42R	CYP2D6	rs5030862	42130668
2090825	73	122C>T	g.42130670G>A	g.5141C>T	p.P41L	CYP2D6	rs373243894	42130670
777817	105	100C>T	g.42130692G>A	g.5119C>T	p.P34S	CYP2D6	rs1065852	42130692
777816	105	82C>T	g.42130710G>A	g.5101C>T	p.R28C	CYP2D6	rs138100349	42130710
4058570	35	18692A>G	g.15878920T>C	g.24155A>G	p.T472A	CYP4F2	rs4020346	15878920
2784563	60	7207G>T	g.15890405C>A	g.12670G>T	p.G185V	CYP4F2	rs3093153	15890405
3684990	43	c.38T>G	g.38433867T>G	g.5168T>G	p.L13R	RYR1	rs193922744	38433867
3684991	43	c.51_53del	g.38440750_38440752delTGA	g.12051_12053delTGA	p.D17del	RYR1	rs193922745	38440750
3684996	43	c.131G>A	g.38440830G>A	g.12131G>A	p.R44H	RYR1	rs139161723	38440830
3684997	43	c.152C>A	g.38440851C>A	g.12152C>A	p.T51N	RYR1	rs193922749	38440851
3684999	43	c.190T>C	g.38442373T>C	g.13674T>C	p.C64R	RYR1	rs995399438	38442373
3685006	43	c.479A>G	g.38444203A>G	g.15504A>G	p.E160G	RYR1	rs193922752	38444203
779106	105	c.487C>T	g.38444211C>T	g.15512C>T	p.R163C	RYR1	rs118192161	38444211
779110	105	c.1021G>A; c.1021G>C	g.38448712G>A; g.38448712G>C	g.20013G>A; g.20013G>C	p.G341R; p.G341R	RYR1	rs121918592	38448712
3685151	43	c.7355G>A; c.7355G>C	g.38500637G>A; g.38500637G>C	g.71938G>A; g.71938G>C	p.R2452Q; p.R2452P	RYR1	rs193922815	38500637
3685171	43	c.8054C>T	g.38504347C>T	g.75648C>T	p.S2685F	RYR1	rs781126470	38504347
3685172	43	c.8188G>C	g.38504868G>C	g.76169G>C	p.D2730H	RYR1	rs193922827	38504868
3685173	43	c.8189A>G	g.38504869A>G	g.76170A>G	p.D2730G	RYR1	rs112196644	38504869
3685298	43	c.14818G>A	g.38585952G>A	g.157253G>A	p.A4940T	RYR1	rs118192158	38585952
779251	105	35230A>G	g.21176804A>G	g.50611A>G	p.N130D	SLCO1B1	rs2306283	21176804
6355127	14	G194R(G>A); G194R(G>C)	g.117535248G>A; g.117535248G>C	g.74465G>A; g.74465G>C	p.G194R	CFTR	rs376008630	117535248
777282	105	S549R(A>C)	g.117587799A>C	g.127016A>C	p.S549R	CFTR	rs121908757	117587799
777619	105	3567C>G; 3567C>T	g.94942249C>G; g.94942249C>T	g.9092C>G; g.9092C>T	p.T130R; p.T130M	CYP2C9	rs200965026	94942249
777904	105	3280G>A	g.42127512C>T	g.8299G>A	p.V370I	CYP2D6	rs61745683	42127512
777903	105	3278T>C	g.42127514A>G	g.8297T>C	p.I369T	CYP2D6	rs1555888899	42127514
777902	105	3269T>C	g.42127523A>G	g.8288T>C	p.F366S	CYP2D6	rs1555888910	42127523
777901	105	3266G>A	g.42127526C>T	g.8285G>A	p.R365H	CYP2D6	rs1058172	42127526
777898	105	3227A>G	g.42127565T>C	g.8246A>G	p.H352R	CYP2D6	rs61736517	42127565
777897	105	3203G>A	g.42127589C>T	g.8222G>A	p.R344Q	CYP2D6	rs76088846	42127589
777896	105	3202C>T	g.42127590G>A	g.8221C>T	p.R344X	CYP2D6	rs72549347	42127590
777894	105	3190G>A	g.42127602C>T	g.8209G>A	p.G340R	CYP2D6	rs566108360	42127602
2090910	73	3187A>C	g.42127605T>G	g.8206A>C	p.I339L	CYP2D6	rs141824015	42127605
777893	105	3184G>A	g.42127608C>T	g.8203G>A	p.V338M	CYP2D6	rs59421388	42127608
777892	105	3182A>G	g.42127610T>C	g.8201A>G	p.D337G	CYP2D6	rs748712690	42127610
777891	105	3181G>A	g.42127611C>T	g.8200G>A	p.D337N	CYP2D6	rs78209835	42127611
777889	105	3161G>C	g.42127631C>G	g.8180G>C	p.R330P	CYP2D6	rs141009491	42127631
777888	105	2989G>A	g.42127803C>T	g.8008G>A	splicing defect	CYP2D6	rs28371725	42127803
777887	105	2951G>C	g.42127841C>G	g.7970G>C	splicing defect	CYP2D6	rs72549349	42127841
1103051	93	2928delGATCCTACATCCGGATGTG	g.42127846_42127864del	g.7947_7965del	p.M321fs	CYP2D6	rs730882170	42127846
777886	105	2940G>A	g.42127852C>T	g.7959G>A	splicing defect	CYP2D6	rs79292917	42127852
777885	105	2936A>C	g.42127856T>G	g.7955A>C	p.H324P	CYP2D6	rs5030867	42127856
777883	105	2893A>G	g.42127899T>C	g.7912A>G	p.T310A	CYP2D6	\N	42127899
777882	105	2870T>C	g.42127922A>G	g.7889T>C	p.L302P	CYP2D6	rs1406719554	42127922
777881	105	2854A>C	g.42127938T>G	g.7873A>C	p.I297L	CYP2D6	rs949717872	42127938
777880	105	2851C>T	g.42127941G>A	g.7870C>T	p.R296C	CYP2D6	rs16947	42127941
1103046	93	2829delC	g.42127963del	g.7848del	p.S288fs	CYP2D6	rs267608279	42127963
777878	105	2819A>G	g.42127973T>C	g.7838A>G	p.N285S	CYP2D6	rs1135829	42127973
1103044	93	2616delAAG	g.42128176_42128178del	g.7635_7637del	p.K281del	CYP2D6	rs5030656	42128176
777876	105	2611T>A	g.42128181A>T	g.7630T>A	p.M279K	CYP2D6	rs1135828	42128181
777875	105	2607G>A	g.42128185C>T	g.7626G>A	p.E278K	CYP2D6	rs77913725	42128185
777871	105	2575C>A	g.42128217G>T	g.7594C>A	p.P267H	CYP2D6	rs148769737	42128217
1103040	93	2580_2581insC	g.42128218dup	g.7599dup	p.R269fs	CYP2D6	rs72549352	42128218
777870	105	2557C>T	g.42128235G>A	g.7576C>T	p.T261I	CYP2D6	rs267608297	42128235
1103036	93	2550delA	g.42128242del	g.7569del	p.R259fs	CYP2D6	rs35742686	42128242
1103035	93	2540delAACT	g.42128251_42128254del	g.7559_7562del	p.T256fs	CYP2D6	rs72549353	42128251
777867	105	2520A>C	g.42128272T>G	g.7539A>C	p.T249P	CYP2D6	\N	42128272
777866	105	2484G>T	g.42128308C>A	g.7503G>T	p.A237S	CYP2D6	rs28371717	42128308
777864	105	2463C>T	g.42128329G>A	g.7482C>T	p.L230F	CYP2D6	rs373813287	42128329
2090878	73	2452C>T	g.42128340G>A	g.7471C>T	p.A226V	CYP2D6	rs140900383	42128340
777863	105	2441G>A	g.42128351C>T	g.7460G>A	splicing defect	CYP2D6	rs377725912	42128351
1103029	93	1996delC	g.42128796del	g.7015del	p.L220fs	CYP2D6	\N	42128796
777861	105	1980T>C	g.42128812A>G	g.6999T>C	p.L213P	CYP2D6	rs199535154	42128812
2676644	62	1973_1974insG	g.42128820dup	g.6992dup	p.E211fs	CYP2D6	rs763609904	42128820
777859	105	1944G>A	g.42128848C>T	g.6963G>A	p.R201H	CYP2D6	rs745365204	42128848
777815	105	77G>A	g.42130715C>T	g.5096G>A	p.R26H	CYP2D6	rs28371696	42130715
777814	105	73C>T	g.42130719G>A	g.5092C>T	p.R25W	CYP2D6	rs267608313	42130719
1102979	93	64delC	g.42130729del	g.5083del	p.L22X	CYP2D6	\N	42130729
777812	105	31G>A	g.42130761C>T	g.5050G>A	p.V11M	CYP2D6	rs769258	42130761
777811	105	19G>A	g.42130773C>T	g.5038G>A	p.V7M	CYP2D6	rs72549358	42130773
777810	105	14C>T	g.42130778G>A	g.5033C>T	p.A5V	CYP2D6	rs773790593	42130778
948658	97	c.299_302del	g.97740411ATGA[1]	g.185642TCAT[1]	\N	DPYD	rs72549309	97740411
778275	105	c.1278G>T	g.97573821C>A	g.352239G>T	p.M426I	DPYD	rs764666241	97573821
778277	105	c.1314T>G	g.97573785A>C	g.352275T>G	p.F438L	DPYD	rs186169810	97573785
778281	105	c.1403C>A	g.97549681G>T	g.376379C>A	p.T468N	DPYD	rs199549923	97549681
778309	105	c.2336C>A	g.97234958G>T	g.691102C>A	p.T779N	DPYD	rs199634007	97234958
778512	105	c.202G>A	g.154536002C>T	g.16571G>A	p.V68M	G6PD	rs1050828	154536002
778539	105	c.487G>A	g.154534495C>T	g.18078G>A	p.G163S	G6PD	rs137852314	154534495
778551	105	c.561_563delCTC	g.154534419_154534421delGAG	g.18152_18154delCTC	p.S188del	G6PD	\N	154534419
778614	105	c.1154G>T	g.154532700C>A	g.19873G>T	p.C385F	G6PD	\N	154532700
778624	105	c.1180G>C	g.154532674C>G	g.19899G>C	p.V394L	G6PD	rs137852335	154532674
778625	105	c.1187C>T	g.154532667G>A	g.19906C>T	p.P396L	G6PD	\N	154532667
778626	105	c.1192G>A	g.154532662C>T	g.19911G>A	p.E398K	G6PD	rs137852325	154532662
778627	105	c.1193A>G	g.154532661T>C	g.19912A>G	p.E398G	G6PD	\N	154532661
778628	105	c.1205C>A	g.154532649G>T	g.19924C>A	p.T402N	G6PD	\N	154532649
778629	105	c.1215G>A	g.154532639C>T	g.19934G>A	p.M405I	G6PD	\N	154532639
778630	105	c.1220A>C	g.154532634T>G	g.19939A>C	p.K407T	G6PD	\N	154532634
778631	105	c.1225C>T	g.154532629G>A	g.19944C>T	p.P409S	G6PD	\N	154532629
778633	105	c.1228G>T	g.154532626C>A	g.19947G>T	p.G410C	G6PD	rs137852323	154532626
2406921	67	c.1376G>T;c.1376G>C	g.154532269C>A;g.154532269C>G	g.20304G>T;g.20304G>C	p.R459L;p.R459P	G6PD	rs72554665	154532269
3685100	43	c.6544A>T	g.38494621A>T	g.65922A>T	p.I2182F	RYR1	rs193922790	38494621
779378	105	514T>C	g.18133870A>G	g.26274T>C	p.S172P	TPMT	rs772832951	18133870
779379	105	537G>T	g.18133847C>A	g.26297G>T	p.Q179H	TPMT	rs6921269	18133847
777651	105	42615T>C	g.94981297T>C	g.48140T>C	p.I359T	CYP2C9	rs56165452	94981297
777935	105	4214G>A	g.42126578C>T	g.9233G>A	p.R497H	CYP2D6	rs1440526469	42126578
777934	105	4187C>T	g.42126605G>A	g.9206C>T	p.S488F	CYP2D6	rs568495591	42126605
777922	105	4129C>G	g.42126663G>C	g.9148C>G	p.P469A	CYP2D6	rs1135833	42126663
777921	105	4111C>G	g.42126681G>C	g.9130C>G	p.H463D	CYP2D6	\N	42126681
777920	105	4095C>A	g.42126697G>T	g.9114C>A	p.F457L	CYP2D6	\N	42126697
2090937	73	4077G>A	g.42126715C>T	g.9096G>A	p.M451I	CYP2D6	rs760940331	42126715
777919	105	4073G>A	g.42126719C>T	g.9092G>A	p.R450H	CYP2D6	rs369177208	42126719
777918	105	4057G>A	g.42126735C>T	g.9076G>A	p.G445R	CYP2D6	rs751092905	42126735
777917	105	4046G>A	g.42126746C>T	g.9065G>A	p.R441H	CYP2D6	rs532668079	42126746
777916	105	4045C>T	g.42126747G>A	g.9064C>T	p.R441C	CYP2D6	rs730882251	42126747
777915	105	4043G>A	g.42126749C>T	g.9062G>A	p.R440H	CYP2D6	rs267608319	42126749
777914	105	4040G>A	g.42126752C>T	g.9059G>A	p.G439D	CYP2D6	rs569439709	42126752
777913	105	3915C>T	g.42126877G>A	g.8934C>T	p.P430L	CYP2D6	rs3021084	42126877
777912	105	3896C>T	g.42126896G>A	g.8915C>T	p.Q424X	CYP2D6	rs763964554	42126896
777911	105	3878G>A	g.42126914C>T	g.8897G>A	p.E418K	CYP2D6	rs28371733	42126914
777910	105	3866C>T	g.42126926G>A	g.8885C>T	p.R414C	CYP2D6	rs747089665	42126926
777909	105	3854G>A	g.42126938C>T	g.8873G>A	p.E410K	CYP2D6	rs769157652	42126938
777908	105	3836A>C	g.42126956T>G	g.8855A>C	p.K404Q	CYP2D6	rs1931013246	42126956
2676699	62	3830G>C	g.42126962C>G	g.8849G>C	p.V402L	CYP2D6	rs1602566413	42126962
1103074	93	3810delTC	g.42126982_42126983del	g.8829_8830del	p.L395fs	CYP2D6	rs757396767	42126982
777906	105	3335G>A	g.42127457C>T	g.8354G>A	p.R388H	CYP2D6	rs77312092	42127457
777905	105	3319G>A	g.42127473C>T	g.8338G>A	p.E383K	CYP2D6	rs75386357	42127473
777899	105	3236A>G	g.42127556T>C	g.8255A>G	p.Y355C	CYP2D6	rs202102799	42127556
777890	105	3173A>C	g.42127619T>G	g.8192A>C	p.E334A	CYP2D6	rs72549348	42127619
2090890	73	2591_2592insT	g.42128201dup	g.7610dup	p.E273X	CYP2D6	rs368858603	42128201
777872	105	2580C>T	g.42128212G>A	g.7599C>T	p.R269X	CYP2D6	rs367543000	42128212
777865	105	2467T>C	g.42128325A>G	g.7486T>C	p.L231P	CYP2D6	rs17002853	42128325
2676652	62	2465delCCT	g.42128326GGA[1]	g.7481CCT[1]	p.L231del	CYP2D6	rs777691989	42128326
778211	105	6981A>G	g.99672916T>C	g.12083A>G	splicing defect	CYP3A5	rs776746	99672916
2406779	67	c.185C>T;c.185C>A	g.154536019G>A;g.154536019G>T	g.16554C>T;g.16554C>A	p.P62L;p.P62H	G6PD	\N	154536019
828071	104	663A>G	m.663A>G	\N	\N	MT-RNR1	rs56489998	663
779061	105	7974G>A	g.48045720G>A	g.13154G>A	p.R139H	NUDT15	rs147390019	48045720
779062	105	8025T>A	g.48045771T>A	g.13205T>A	p.L156Q	NUDT15	rs139551410	48045771
3685014	43	c.529C>T	g.38444253C>T	g.15554C>T	p.R177C	RYR1	rs193922757	38444253
3685015	43	c.533A>G; c.533A>C	g.38444257A>G; g.38444257A>C	g.15558A>G; g.15558A>C	p.Y178C; p.Y178S	RYR1	\N	38444257
3685016	43	c.625G>A	g.38444671G>A	g.15972G>A	p.E209K	RYR1	rs771058055	38444671
3685017	43	c.641C>T	g.38446481C>T	g.17782C>T	p.T214M	RYR1	rs727504129	38446481
3685018	43	c.652G>A	g.38446492G>A	g.17793G>A	p.V218I	RYR1	rs193922759	38446492
3685019	43	c.677T>A	g.38446517T>A	g.17818T>A	p.M226K	RYR1	rs112596687	38446517
3685020	43	c.680A>T	g.38446520A>T	g.17821A>T	p.D227V	RYR1	rs193922760	38446520
3685021	43	c.742G>A; c.742G>C	g.38446710G>A; g.38446710G>C	g.18011G>A; g.18011G>C	p.G248R; p.G248R	RYR1	rs1801086	38446710
3685022	43	c.946C>T	g.38448500C>T	g.19801C>T	p.R316C	RYR1	rs752652072	38448500
3685031	43	c.1202G>T; c.1202G>A	g.38451843G>T; g.38451843G>A	g.23144G>T; g.23144G>A	p.R401L; p.R401H	RYR1	rs193922766	38451843
779112	105	c.1209C>G	g.38451850C>G	g.23151C>G	p.I403M	RYR1	rs118192116	38451850
3685033	43	c.1411C>T	g.38452985C>T	g.24286C>T	p.R471C	RYR1	rs1376393998	38452985
3685034	43	c.1422G>T	g.38452996G>T	g.24297G>T	p.Q474H	RYR1	rs193922767	38452996
3685035	43	c.1453A>G	g.38455247A>G	g.26548A>G	p.M485V	RYR1	rs147723844	38455247
3685036	43	c.1459C>G	g.38455253C>G	g.26554C>G	p.L487V	RYR1	\N	38455253
3685037	43	c.1460T>C	g.38455254T>C	g.26555T>C	p.L487P	RYR1	\N	38455254
3685038	43	c.1475G>A	g.38455269G>A	g.26570G>A	p.R492H	RYR1	rs901087791	38455269
3685039	43	c.1553T>C	g.38455347T>C	g.26648T>C	p.V518A	RYR1	\N	38455347
3685040	43	c.1565A>C; c.1565A>G	g.38455359A>C; g.38455359A>G	g.26660A>C; g.26660A>G	p.Y522S; p.Y522C	RYR1	rs118192162	38455359
779114	105	c.1589G>A	g.38455463G>A	g.26764G>A	p.R530H	RYR1	rs111888148	38455463
3685042	43	c.1597C>T; c.1597C>A	g.38455471C>T; g.38455471C>A	g.26772C>T; g.26772C>A	p.R533C; p.R533S	RYR1	rs193922768	38455471
779116	105	c.1598G>A	g.38455472G>A	g.26773G>A	p.R533H	RYR1	rs144336148	38455472
3824632	38	c.1615T>C; c.1615T>G	g.38455489T>C; g.38455489T>G	g.26790T>C; g.26790T>G	p.F539L; p.F539V	RYR1	rs193922769	38455489
3685046	43	c.1630G>T	g.38455504G>T	g.26805G>T	p.D544Y	RYR1	\N	38455504
779117	105	c.1654C>T	g.38455528C>T	g.26829C>T	p.R552W	RYR1	rs193922770	38455528
3685048	43	c.1834G>C	g.38457539G>C	g.28840G>C	p.A612P	RYR1	rs118204423	38457539
779118	105	c.1840C>T	g.38457545C>T	g.28846C>T	p.R614C	RYR1	rs118192172	38457545
779119	105	c.1841G>T	g.38457546G>T	g.28847G>T	p.R614L	RYR1	rs193922772	38457546
3685051	43	c.2050G>C	g.38458175G>C	g.29476G>C	p.G684R	RYR1	rs747177274	38458175
3685052	43	c.2122G>A	g.38458247G>A	g.29548G>A	p.D708N	RYR1	rs138874610	38458247
3685053	43	c.2447C>T	g.38460461C>T	g.31762C>T	p.P816L	RYR1	rs376149732	38460461
3685054	43	c.2537C>T	g.38460551C>T	g.31852C>T	p.S846L	RYR1	rs193922775	38460551
3685055	43	c.2654G>A	g.38463499G>A	g.34800G>A	p.R885H	RYR1	rs370634440	38463499
3685056	43	c.2797G>A	g.38464649G>A	g.35950G>A	p.A933T	RYR1	rs148623597	38464649
3685057	43	c.2924G>A	g.38466144G>A	g.37445G>A	p.R975Q	RYR1	rs778241277	38466144
3685059	43	c.3095G>A	g.38466315G>A	g.37616G>A	p.R1032H	RYR1	rs141942845	38466315
3685060	43	c.3127C>T	g.38466347C>T	g.37648C>T	p.R1043C	RYR1	rs111272095	38466347
3685066	43	c.3527C>T	g.38469111C>T	g.40412C>T	p.T1176I	RYR1	rs549201486	38469111
3685077	43	c.5033A>G	g.38485688A>G	g.56989A>G	p.N1678S	RYR1	rs781104539	38485688
777303	105	711+3A->G	g.117534368A>G	g.73585A>G	Intronic	CFTR	rs397508761	117534368
948626	97	27126_27127insT	g.99652771dup	g.32228dup	p.T346fs	CYP3A5	rs41303343	99652771
778215	105	19381G>A	g.99660516C>T	g.24483G>A	p.A337T	CYP3A5	rs28383479	99660516
778214	105	14685G>A	g.99665212C>T	g.19787G>A	splicing defect	CYP3A5	rs10264272	99665212
778210	105	3699C>T	g.99676198G>A	g.8801C>T	p.R28C	CYP3A5	rs55817950	99676198
2784565	60	18833C>A	g.15878779G>T	g.24296C>A	p.L519M	CYP4F2	rs3093200	15878779
3318569	49	18200G>A	g.15879412C>T	g.23663G>A	p.R444H	CYP4F2	rs138971789	15879412
778237	105	17991G>A	g.15879621C>T	g.23454G>A	p.V433M	CYP4F2	rs2108622	15879621
3318567	49	11594C>G	g.15886018G>C	g.17057C>G	p.L341V	CYP4F2	rs145174239	15886018
3318566	49	7941G>T	g.15889671C>A	g.13404G>T	p.A224S	CYP4F2	rs144233412	15889671
3318564	49	5071G>A	g.15892541C>T	g.10534G>A	p.E129K	CYP4F2	rs145875499	15892541
7094174	9	930G>A	m.930G>A	\N	\N	MT-RNR1	rs41352944	930
3685008	43	c.488G>T; c.488G>A	g.38444212G>T; g.38444212G>A	g.15513G>T; g.15513G>A	p.R163L; p.R163H	RYR1	rs193922753	38444212
3685058	43	c.2996G>A	g.38466216G>A	g.37517G>A	p.R999H	RYR1	rs180714609	38466216
3824648	38	c.3166G>C; c.3166G>A	g.38466386G>C; g.38466386G>A	g.37687G>C; g.37687G>A	p.D1056H; p.D1056N	RYR1	rs2145447772	38466386
3685063	43	c.3172G>A	g.38466392G>A	g.37693G>A	p.E1058K	RYR1	\N	38466392
3685064	43	c.3224G>A	g.38467655G>A	g.38956G>A	p.R1075Q	RYR1	rs749040743	38467655
3685065	43	c.3418C>T	g.38469002C>T	g.40303C>T	p.R1140C	RYR1	rs193922776	38469002
3685067	43	c.3656A>C	g.38469404A>C	g.40705A>C	p.Q1219P	RYR1	\N	38469404
3685068	43	c.3667G>A	g.38469415G>A	g.40716G>A	p.E1223K	RYR1	rs936513262	38469415
3685069	43	c.4024A>G	g.38473635A>G	g.44936A>G	p.S1342G	RYR1	rs34694816	38473635
3685070	43	c.4178A>G	g.38475335A>G	g.46636A>G	p.K1393R	RYR1	rs137933390	38475335
3685071	43	c.4400A>G	g.38477816A>G	g.49117A>G	p.K1467R	RYR1	rs145573319	38477816
3685072	43	c.4711A>G	g.38483293A>G	g.54594A>G	p.I1571V	RYR1	rs146429605	38483293
3685073	43	c.4747C>T	g.38483329C>T	g.54630C>T	p.R1583C	RYR1	rs754476250	38483329
3685074	43	c.4763C>T	g.38483345C>T	g.54646C>T	p.P1588L	RYR1	rs151029675	38483345
3685075	43	c.4775C>T	g.38483357C>T	g.54658C>T	p.P1592L	RYR1	rs193922777	38483357
3685076	43	c.5024T>C	g.38485679T>C	g.56980T>C	p.L1675P	RYR1	\N	38485679
3685078	43	c.5036G>A	g.38485691G>A	g.56992G>A	p.R1679H	RYR1	rs146504767	38485691
3685079	43	c.5132A>G	g.38485787A>G	g.57088A>G	p.Y1711C	RYR1	rs754785770	38485787
3685080	43	c.5183C>T	g.38485838C>T	g.57139C>T	p.S1728F	RYR1	rs193922781	38485838
3685081	43	c.5186T>G	g.38485841T>G	g.57142T>G	p.M1729R	RYR1	rs193922782	38485841
3685082	43	c.5317C>T	g.38485972C>T	g.57273C>T	p.P1773S	RYR1	rs192863857	38485972
3685083	43	c.5341T>C	g.38485996T>C	g.57297T>C	p.C1781R	RYR1	rs372958050	38485996
3685084	43	c.5360C>T	g.38486015C>T	g.57316C>T	p.P1787L	RYR1	rs34934920	38486015
3685085	43	c.5440A>G	g.38486095A>G	g.57396A>G	p.M1814V	RYR1	\N	38486095
3685086	43	c.5441T>A	g.38486096T>A	g.57397T>A	p.M1814K	RYR1	rs193922783	38486096
3685087	43	c.5890C>T	g.38490151C>T	g.61452C>T	p.R1964C	RYR1	rs145801146	38490151
3685088	43	c.6037A>C	g.38490642A>C	g.61943A>C	p.K2013Q	RYR1	\N	38490642
3685089	43	c.6178G>T	g.38492540G>T	g.63841G>T	p.G2060C	RYR1	rs35364374	38492540
3685090	43	c.6302T>A	g.38494379T>A	g.65680T>A	p.M2101K	RYR1	rs746818096	38494379
3685091	43	c.6304G>C	g.38494381G>C	g.65682G>C	p.V2102L	RYR1	rs770593660	38494381
3685092	43	c.6349G>C	g.38494426G>C	g.65727G>C	p.V2117L	RYR1	rs193922788	38494426
3685093	43	c.6377G>A	g.38494454G>A	g.65755G>A	p.R2126Q	RYR1	\N	38494454
3685094	43	c.6387C>G	g.38494464C>G	g.65765C>G	p.D2129E	RYR1	rs117886618	38494464
3685095	43	c.6388G>A	g.38494465G>A	g.65766G>A	p.G2130R	RYR1	rs193922789	38494465
3685096	43	c.6478G>A	g.38494555G>A	g.65856G>A	p.G2160S	RYR1	rs143398211	38494555
779120	105	c.6487C>T	g.38494564C>T	g.65865C>T	p.R2163C	RYR1	rs118192175	38494564
779122	105	c.6502G>A	g.38494579G>A	g.65880G>A	p.V2168M	RYR1	rs118192176	38494579
3685101	43	c.6548G>A	g.38494625G>A	g.65926G>A	p.G2183E	RYR1	rs959170123	38494625
3685102	43	c.6599C>T	g.38496265C>T	g.67566C>T	p.A2200V	RYR1	rs193922791	38496265
3685103	43	c.6612C>G	g.38496278C>G	g.67579C>G	p.H2204Q	RYR1	rs141646642	38496278
779123	105	c.6617C>G; c.6617C>T	g.38496283C>G; g.38496283C>T	g.67584C>G; g.67584C>T	p.T2206R; p.T2206M	RYR1	rs118192177	38496283
3685105	43	c.6628G>T	g.38496294G>T	g.67595G>T	p.V2210F	RYR1	rs193922792	38496294
3685106	43	c.6635T>A	g.38496301T>A	g.67602T>A	p.V2212D	RYR1	rs193922793	38496301
3685107	43	c.6640G>A	g.38496306G>A	g.67607G>A	p.V2214I	RYR1	rs193922795	38496306
3685110	43	c.6710G>A	g.38496455G>A	g.67756G>A	p.C2237Y	RYR1	\N	38496455
3685111	43	c.6742C>T	g.38496487C>T	g.67788C>T	p.R2248C	RYR1	rs763352221	38496487
3685112	43	c.6743G>A	g.38496488G>A	g.67789G>A	p.R2248H	RYR1	rs140152019	38496488
3685113	43	c.6757C>T	g.38496502C>T	g.67803C>T	p.H2253Y	RYR1	rs917523269	38496502
3685114	43	c.6838G>A	g.38496901G>A	g.68202G>A	p.V2280I	RYR1	rs193922797	38496901
779124	105	c.7007G>A	g.38499223G>A	g.70524G>A	p.R2336H	RYR1	rs112563513	38499223
3685118	43	c.7018T>C	g.38499234T>C	g.70535T>C	p.F2340L	RYR1	\N	38499234
3685119	43	c.7025A>G	g.38499241A>G	g.70542A>G	p.N2342S	RYR1	rs147213895	38499241
3685120	43	c.7032G>C	g.38499639G>C	g.70940G>C	p.E2344D	RYR1	rs193922798	38499639
3685121	43	c.7035C>A	g.38499642C>A	g.70943C>A	p.S2345R	RYR1	\N	38499642
3685122	43	c.7036G>A	g.38499643G>A	g.70944G>A	p.V2346M	RYR1	rs193922799	38499643
6970264	10	1A>T	g.21141575A>T	g.15382A>T	p.M1L	SLCO1B1	rs185905373	21141575
6970265	10	31101G>C	g.21172675G>C	g.46482G>C	p.S37T	SLCO1B1	rs556524705	21172675
6970267	10	31161G>A	g.21172735G>A	g.46542G>A	p.R57Q	SLCO1B1	rs61760182	21172735
6970272	10	35297G>C	g.21176871G>C	g.50678G>C	p.R152T	SLCO1B1	rs145144129	21176871
777268	105	E56K	g.117509035G>A	g.48252G>A	p.E56K	CFTR	rs397508256	117509035
3318563	49	2085C>T	g.15895527G>A	g.7548C>T	p.R108W	CYP4F2	rs114396708	15895527
3318562	49	2052C>A	g.15895560G>T	g.7515C>A	p.P97T	CYP4F2	rs144455532	15895560
3318561	49	146G>A	g.15897466C>T	g.5609G>A	p.R49Q	CYP4F2	rs201380574	15897466
3318560	49	139C>T	g.15897473G>A	g.5602C>T	p.R74C	CYP4F2	rs115517770	15897473
2784562	60	46G>C	g.15897566C>G	g.5509G>C	p.A16P	CYP4F2	rs114099324	15897566
778236	105	34T>G	g.15897578A>C	g.5497T>G	p.W12G	CYP4F2	rs3093105	15897578
778255	105	c.557A>G	g.97699474T>C	g.226586A>G	p.Y186C	DPYD	rs115232898	97699474
778257	105	c.632A>G	g.97699399T>C	g.226661A>G	p.Y211C	DPYD	rs72549307	97699399
778258	105	c.703C>T	g.97691776G>A	g.234284C>T	p.R235W	DPYD	rs1801266	97691776
778259	105	c.775A>G	g.97679170T>C	g.246890A>G	p.K259E	DPYD	rs45589337	97679170
778260	105	c.868A>G	g.97595149T>C	g.330911A>G	p.K290E	DPYD	rs146356975	97595149
778261	105	c.929T>C	g.97595088A>G	g.330972T>C	p.L310S	DPYD	rs150437414	97595088
778262	105	c.934C>T	g.97595083G>A	g.330977C>T	p.L312F	DPYD	rs145112791	97595083
778263	105	c.967G>A	g.97593379C>T	g.332681G>A	p.A323T	DPYD	rs201018345	97593379
778264	105	c.1003G>T	g.97593343C>A	g.332717G>T	p.V335L	DPYD	rs72549306	97593343
778265	105	c.1024G>A	g.97593322C>T	g.332738G>A	p.D342N	DPYD	rs183385770	97593322
778266	105	c.1057C>T	g.97593289G>A	g.332771C>T	p.R353C	DPYD	rs143154602	97593289
778267	105	c.1108A>G	g.97593238T>C	g.332822A>G	p.I370V	DPYD	rs72549305	97593238
778268	105	c.1129-5923C>G	g.97579893G>C	g.346167C>G	splicing defect	DPYD	rs75017182	97579893
778270	105	c.1156G>T	g.97573943C>A	g.352117G>T	p.E386X	DPYD	rs78060119	97573943
778271	105	c.1180C>T	g.97573919G>A	g.352141C>T	p.R394W	DPYD	rs140602333	97573919
778272	105	c.1181G>T	g.97573918C>A	g.352142G>T	p.R394L	DPYD	rs143815742	97573918
778273	105	c.1218G>A	g.97573881C>T	g.352179G>A	p.M406I	DPYD	rs61622928	97573881
778269	105	c.1236G>A	g.97573863C>T	g.352197G>A	\N	DPYD	rs56038477	97573863
778274	105	c.1260T>A	g.97573839A>T	g.352221T>A	p.N420K	DPYD	rs200064537	97573839
778276	105	c.1294G>A	g.97573805C>T	g.352255G>A	p.D432N	DPYD	rs142512579	97573805
778278	105	c.1349C>T	g.97549735G>A	g.376325C>T	p.A450V	DPYD	rs72975710	97549735
778279	105	c.1358C>G	g.97549726G>C	g.376334C>G	p.P453R	DPYD	rs144395748	97549726
778280	105	c.1371C>T	g.97549713G>A	g.376347C>T	p.N457N	DPYD	rs57918000	97549713
778282	105	c.1475C>T	g.97549609G>A	g.376451C>T	p.S492L	DPYD	rs72549304	97549609
778284	105	c.1519G>A	g.97549565C>T	g.376495G>A	p.V507I	DPYD	rs138391898	97549565
778285	105	c.1543G>A	g.97515923C>T	g.410137G>A	p.V515I	DPYD	rs148994843	97515923
778286	105	c.1577C>G	g.97515889G>C	g.410171C>G	p.T526S	DPYD	rs190951787	97515889
778287	105	c.1601G>A	g.97515865C>T	g.410195G>A	p.S534N	DPYD	rs1801158	97515865
3685115	43	c.6847A>C	g.38496910A>C	g.68211A>C	p.N2283H	RYR1	rs118192121	38496910
3685116	43	c.6961A>G	g.38499177A>G	g.70478A>G	p.I2321V	RYR1	rs34390345	38499177
779125	105	c.7042_7044del	g.38499646_38499648delGAG	g.70947_70949delGAG	p.E2348del	RYR1	rs121918596	38499646
3685124	43	c.7043A>G	g.38499650A>G	g.70951A>G	p.E2348G	RYR1	rs193922801	38499650
779126	105	c.7048G>A	g.38499655G>A	g.70956G>A	p.A2350T	RYR1	rs193922802	38499655
3685126	43	c.7060G>A	g.38499667G>A	g.70968G>A	p.V2354M	RYR1	\N	38499667
779127	105	c.7063C>T	g.38499670C>T	g.70971C>T	p.R2355W	RYR1	rs193922803	38499670
3685128	43	c.7073T>A	g.38499680T>A	g.70981T>A	p.I2358N	RYR1	\N	38499680
3685129	43	c.7076G>A	g.38499683G>A	g.70984G>A	p.R2359Q	RYR1	\N	38499683
3685130	43	c.7075C>T	g.38499682C>T	g.70983C>T	p.R2359W	RYR1	rs769482889	38499682
3685131	43	c.7084G>A	g.38499691G>A	g.70992G>A	p.E2362K	RYR1	rs762401851	38499691
3685132	43	c.7085A>G	g.38499692A>G	g.70993A>G	p.E2362G	RYR1	rs193922804	38499692
3685133	43	c.7089C>G	g.38499696C>G	g.70997C>G	p.C2363W	RYR1	\N	38499696
3685135	43	c.7097C>G	g.38499704C>G	g.71005C>G	p.P2366R	RYR1	rs193922806	38499704
3685136	43	c.7099G>A	g.38499706G>A	g.71007G>A	p.A2367T	RYR1	rs146306934	38499706
3685137	43	c.7112A>G	g.38499719A>G	g.71020A>G	p.E2371G	RYR1	\N	38499719
3685138	43	c.7123G>A	g.38499730G>A	g.71031G>A	p.G2375R	RYR1	\N	38499730
779128	105	c.7124G>C	g.38499731G>C	g.71032G>C	p.G2375A	RYR1	rs193922807	38499731
3685140	43	c.7199A>G	g.38499806A>G	g.71107A>G	p.D2400G	RYR1	rs976108591	38499806
3685141	43	c.7210G>A	g.38499817G>A	g.71118G>A	p.E2404K	RYR1	rs111364296	38499817
779129	105	c.7282G>A	g.38499975G>A	g.71276G>A	p.A2428T	RYR1	rs193922809	38499975
3685144	43	c.7292A>T	g.38499985A>T	g.71286A>T	p.D2431V	RYR1	\N	38499985
779130	105	c.7300G>A	g.38499993G>A	g.71294G>A	p.G2434R	RYR1	rs121918593	38499993
3685146	43	c.7304G>A; c.7304G>T	g.38499997G>A; g.38499997G>T	g.71298G>A; g.71298G>T	p.R2435H; p.R2435L	RYR1	rs28933396	38499997
3685147	43	c.7307G>A	g.38500000G>A	g.71301G>A	p.C2436Y	RYR1	\N	38500000
3685148	43	c.7310C>T	g.38500003C>T	g.71304C>T	p.A2437V	RYR1	rs193922812	38500003
3685149	43	c.7317G>C	g.38500010G>C	g.71311G>C	p.E2439D	RYR1	rs193922813	38500010
779132	105	c.7354C>T	g.38500636C>T	g.71937C>T	p.R2452W	RYR1	rs118192124	38500636
3685152	43	c.7358T>C	g.38500640T>C	g.71941T>C	p.I2453T	RYR1	rs118192123	38500640
779133	105	c.7360C>T	g.38500642C>T	g.71943C>T	p.R2454C	RYR1	rs193922816	38500642
779134	105	c.7361G>A	g.38500643G>A	g.71944G>A	p.R2454H	RYR1	rs118192122	38500643
779135	105	c.7372C>T	g.38500654C>T	g.71955C>T	p.R2458C	RYR1	rs28933397	38500654
3685156	43	c.7373G>A; c.7373G>T	g.38500655G>A; g.38500655G>T	g.71956G>A; g.71956G>T	p.R2458H; p.R2458L	RYR1	rs121918594	38500655
3685157	43	c.7385C>T	g.38500667C>T	g.71968C>T	p.P2462L	RYR1	rs551223467	38500667
3685162	43	c.7760A>G	g.38502652A>G	g.73953A>G	p.Y2587C	RYR1	rs767553612	38502652
3685163	43	c.7771C>G; c.7771C>T	g.38502663C>G; g.38502663C>T	g.73964C>G; g.73964C>T	p.R2591G; p.R2591W	RYR1	rs193922822	38502663
779264	105	60979T>G	g.21202553T>G	g.76360T>G	p.F400V	SLCO1B1	rs1228465562	21202553
778246	105	c.62G>A	g.97883352C>T	g.42708G>A	p.R21Q	DPYD	rs80081766	97883352
778247	105	c.85T>C	g.97883329A>G	g.42731T>C	p.C29R	DPYD	rs1801265	97883329
778249	105	c.313G>A	g.97740400C>T	g.185660G>A	p.A105T	DPYD	rs150385342	97740400
778250	105	c.343A>G	g.97721650T>C	g.204410A>G	p.M115V	DPYD	rs141462178	97721650
778251	105	c.451A>G	g.97721542T>C	g.204518A>G	p.N151D	DPYD	rs200562975	97721542
778252	105	c.496A>G	g.97699535T>C	g.226525A>G	p.M166V	DPYD	rs2297595	97699535
778253	105	c.498G>A	g.97699533C>T	g.226527G>A	p.M166I	DPYD	rs139834141	97699533
778254	105	c.525G>A	g.97699506C>T	g.226554G>A	p.S175S	DPYD	rs6670886	97699506
778289	105	c.1627A>G	g.97515839T>C	g.410221A>G	p.I543V	DPYD	rs1801159	97515839
778290	105	c.1679T>G	g.97515787A>C	g.410273T>G	p.I560S	DPYD	rs55886062	97515787
778291	105	c.1682G>T	g.97515784C>A	g.410276G>T	p.R561L	DPYD	rs201615754	97515784
778292	105	c.1774C>T	g.97450190G>A	g.475870C>T	p.R592W	DPYD	rs59086055	97450190
778293	105	c.1775G>A	g.97450189C>T	g.475871G>A	p.R592Q	DPYD	rs138616379	97450189
778294	105	c.1777G>A	g.97450187C>T	g.475873G>A	p.G593R	DPYD	rs145773863	97450187
778295	105	c.1796T>C	g.97450168A>G	g.475892T>C	p.M599T	DPYD	rs147601618	97450168
778296	105	c.1896T>C	g.97450068A>G	g.475992T>C	p.F632F	DPYD	rs17376848	97450068
948707	97	c.1898del	g.97450067del	g.475994del	p.P633Qfs	DPYD	rs72549303	97450067
778298	105	c.1905C>G	g.97450059G>C	g.476001C>G	p.N635K	DPYD	rs3918289	97450059
778299	105	c.1905+1G>A	g.97450058C>T	g.476002G>A	splicing defect	DPYD	rs3918290	97450058
778300	105	c.1906A>C	g.97382461T>G	g.543599A>C	p.I636L	DPYD	rs55971861	97382461
778301	105	c.1990G>T	g.97373629C>A	g.552431G>T	p.A664S	DPYD	rs138545885	97373629
778302	105	c.2021G>A	g.97373598C>T	g.552462G>A	p.G674D	DPYD	rs137999090	97373598
778303	105	c.2161G>A	g.97306195C>T	g.619865G>A	p.A721T	DPYD	rs145548112	97306195
778304	105	c.2186C>T	g.97305372G>A	g.620688C>T	p.A729V	DPYD	rs146529561	97305372
778305	105	c.2194G>A	g.97305364C>T	g.620696G>A	p.V732I	DPYD	rs1801160	97305364
778306	105	c.2195T>G	g.97305363A>C	g.620697T>G	p.V732G	DPYD	rs60511679	97305363
778307	105	c.2279C>T	g.97305279G>A	g.620781C>T	p.T760I	DPYD	rs112766203	97305279
778308	105	c.2303C>A	g.97234991G>T	g.691069C>A	p.T768K	DPYD	rs56005131	97234991
778310	105	c.2482G>A	g.97193209C>T	g.732851G>A	p.E828K	DPYD	rs200687447	97193209
778311	105	c.2582A>G	g.97193109T>C	g.732951A>G	p.K861R	DPYD	rs60139309	97193109
778316	105	c.2846A>T	g.97082391T>A	g.843669A>T	p.D949V	DPYD	rs67376798	97082391
778319	105	c.2921A>T	g.97079133T>A	g.846927A>T	p.D974V	DPYD	rs72547602	97079133
778320	105	c.2933A>G	g.97079121T>C	g.846939A>G	p.H978R	DPYD	rs72547601	97079121
778321	105	c.2978T>G	g.97079076A>C	g.846984T>G	p.L993R	DPYD	rs139459586	97079076
3685025	43	c.992_994dup	g.38448680_38448681insGGA	g.19981_19982insGGA	p.E331dup	RYR1	\N	38448680
3685027	43	c.1024G>A	g.38448715G>A	g.20016G>A	p.E342K	RYR1	\N	38448715
3685028	43	c.1100G>A; c.1100G>T	g.38448791G>A; g.38448791G>T	g.20092G>A; g.20092G>T	p.R367Q; p.R367L	RYR1	rs113332073	38448791
3685029	43	c.1144C>A	g.38451785C>A	g.23086C>A	p.H382N	RYR1	\N	38451785
3685178	43	c.8518C>T	g.38505923C>T	g.77224C>T	p.R2840W	RYR1	rs193922830	38505923
3685179	43	c.8527T>C	g.38505932T>C	g.77233T>C	p.S2843P	RYR1	rs768535909	38505932
3685180	43	c.8600T>A	g.38506361T>A	g.77662T>A	p.L2867Q	RYR1	rs193922831	38506361
3685181	43	c.8638G>A	g.38506492G>A	g.77793G>A	p.E2880K	RYR1	rs112772310	38506492
3685182	43	c.8654C>G	g.38506508C>G	g.77809C>G	p.T2885R	RYR1	\N	38506508
3685183	43	c.8729C>T	g.38506865C>T	g.78166C>T	p.T2910M	RYR1	\N	38506865
3685184	43	c.8926C>T	g.38507821C>T	g.79122C>T	p.H2976Y	RYR1	\N	38507821
3685186	43	c.9268G>A	g.38512279G>A	g.83580G>A	p.A3090T	RYR1	\N	38512279
779139	105	c.9310G>A	g.38512321G>A	g.83622G>A	p.E3104K	RYR1	rs193922832	38512321
3685188	43	c.9356G>A	g.38512367G>A	g.83668G>A	p.R3119H	RYR1	rs193922833	38512367
3685189	43	c.9499C>T	g.38515052C>T	g.86353C>T	p.R3167X	RYR1	\N	38515052
3685190	43	c.9635A>G	g.38516167A>G	g.87468A>G	p.E3212G	RYR1	rs199738299	38516167
3685191	43	c.9649T>C	g.38516181T>C	g.87482T>C	p.S3217P	RYR1	\N	38516181
3685192	43	c.9652G>A	g.38516184G>A	g.87485G>A	p.V3218M	RYR1	rs553055844	38516184
3685193	43	c.9676G>C	g.38516208G>C	g.87509G>C	p.E3226Q	RYR1	\N	38516208
3685194	43	c.9758T>C	g.38517431T>C	g.88732T>C	p.I3253T	RYR1	rs375626634	38517431
3685195	43	c.9797T>C	g.38517470T>C	g.88771T>C	p.M3266T	RYR1	\N	38517470
3685197	43	c.9850T>A	g.38517523T>A	g.88824T>A	p.W3284R	RYR1	\N	38517523
3685198	43	c.9868G>A	g.38517541G>A	g.88842G>A	p.E3290K	RYR1	rs112151058	38517541
3685199	43	c.10042C>T	g.38519237C>T	g.90538C>T	p.R3348C	RYR1	rs118204421	38519237
3685200	43	c.10043G>A	g.38519238G>A	g.90539G>A	p.R3348H	RYR1	rs193922834	38519238
3685201	43	c.10097G>A	g.38519292G>A	g.90593G>A	p.R3366H	RYR1	rs137932199	38519292
3685202	43	c.10100A>G	g.38519295A>G	g.90596A>G	p.K3367R	RYR1	rs118192126	38519295
3685203	43	c.10229C>A	g.38519424C>A	g.90725C>A	p.P3410Q	RYR1	\N	38519424
3685204	43	c.10237A>T	g.38519432A>T	g.90733A>T	p.I3413F	RYR1	\N	38519432
3685205	43	c.10252A>G	g.38519447A>G	g.90748A>G	p.N3418D	RYR1	\N	38519447
3685206	43	c.10556C>T	g.38525432C>T	g.96733C>T	p.P3519L	RYR1	\N	38525432
3685207	43	c.10616G>A	g.38525492G>A	g.96793G>A	p.R3539H	RYR1	rs143987857	38525492
3685208	43	c.10747G>C	g.38527707G>C	g.99008G>C	p.E3583Q	RYR1	rs55876273	38527707
3685209	43	c.10750G>C	g.38527710G>C	g.99011G>C	p.E3584Q	RYR1	\N	38527710
3685210	43	c.10891G>T	g.38528372G>T	g.99673G>T	p.A3631S	RYR1	\N	38528372
3685211	43	c.11086G>C	g.38529002G>C	g.100303G>C	p.D3696H	RYR1	\N	38529002
3685212	43	c.11120G>T	g.38529036G>T	g.100337G>T	p.R3707L	RYR1	rs193922838	38529036
3685213	43	c.11126C>T	g.38529042C>T	g.100343C>T	p.A3709V	RYR1	\N	38529042
779365	105	340G>A	g.18143622C>T	g.16522G>A	p.E114K	TPMT	rs115106679	18143622
778318	105	c.2915A>G	g.97079139T>C	g.846921A>G	p.Q972R	DPYD	rs145529148	97079139
778323	105	c.2983G>T	g.97079071C>A	g.846989G>T	p.V995F	DPYD	rs1801268	97079071
778326	105	c.3067C>A	g.97078987G>T	g.847073C>A	p.P1023T	DPYD	rs114096998	97078987
778504	105	c.159G>C	g.154536045C>G	g.16528G>C	p.W53C	G6PD	\N	154536045
778505	105	c.169C>T	g.154536035G>A	g.16538C>T	p.R57W	G6PD	\N	154536035
778506	105	c.170G>A	g.154536034C>T	g.16539G>A	p.R57E	G6PD	\N	154536034
778507	105	c.172G>A	g.154536032C>T	g.16541G>A	p.D58N	G6PD	rs137852315	154536032
778509	105	c.180_182delTCT	g.154536022_154536024delAGA	g.16549_16551delTCT	p.L61del	G6PD	\N	154536022
778511	105	c.196T>A	g.154536008A>T	g.16565T>A	p.P66I	G6PD	\N	154536008
778513	105	c.208T>C	g.154535996A>G	g.16577T>C	p.Y70H	G6PD	rs137852349	154535996
778514	105	c.209A>G	g.154535995T>C	g.16578A>G	p.Y70C	G6PD	rs782090947	154535995
778515	105	c.224T>C	g.154535980A>G	g.16593T>C	p.L75P	G6PD	\N	154535980
778516	105	c.241C>T	g.154535963G>A	g.16610C>T	p.R81C	G6PD	rs138687036	154535963
778517	105	c.242G>A	g.154535962C>T	g.16611G>A	p.R81H	G6PD	rs782308266	154535962
778518	105	c.274C>T	g.154535379G>A	g.17194C>T	p.P92S	G6PD	\N	154535379
778520	105	c.311G>A	g.154535342C>T	g.17231G>A	p.R104H	G6PD	rs181277621	154535342
778521	105	c.317C>G	g.154535336G>C	g.17237C>G	p.S106C	G6PD	rs267606835	154535336
778522	105	c.323T>A	g.154535330A>T	g.17243T>A	p.V108E	G6PD	\N	154535330
778523	105	c.337G>A	g.154535316C>T	g.17257G>A	p.D113N	G6PD	rs5030870	154535316
778524	105	c.352T>C	g.154535301A>G	g.17272T>C	p.Y118H	G6PD	\N	154535301
778525	105	c.375G>T	g.154535278C>A	g.17295G>T	p.M125I	G6PD	\N	154535278
778526	105	c.376A>G	g.154535277T>C	g.17296A>G	p.N126D	G6PD	rs1050829	154535277
778527	105	c.379G>T	g.154535274C>A	g.17299G>T	p.A127S	G6PD	\N	154535274
778529	105	c.384C>T	g.154535269G>A	g.17304C>T	p.L128L	G6PD	\N	154535269
778530	105	c.392G>T	g.154535261C>A	g.17312G>T	p.G131V	G6PD	\N	154535261
778531	105	c.404A>C	g.154535249T>G	g.17324A>C	p.N135T	G6PD	rs782322505	154535249
778532	105	c.406C>T	g.154535247G>A	g.17326C>T	p.R136C	G6PD	\N	154535247
778533	105	c.409C>T	g.154535244G>A	g.17329C>T	p.L137F	G6PD	\N	154535244
778534	105	c.442G>A	g.154535211C>T	g.17362G>A	p.E148K	G6PD	\N	154535211
778535	105	c.463C>G	g.154535190G>C	g.17383C>G	p.H155D	G6PD	\N	154535190
778536	105	c.466G>A	g.154535187C>T	g.17386G>A	p.E156K	G6PD	rs137852313	154535187
778537	105	c.473G>A	g.154535180C>T	g.17393G>A	p.C158Y	G6PD	rs782487723	154535180
778538	105	c.477G>C	g.154535176C>G	g.17397G>C	p.M159I	G6PD	rs370918918	154535176
778548	105	c.535A>T	g.154534447T>A	g.18126A>T	p.S179C	G6PD	\N	154534447
778549	105	c.542A>T	g.154534440T>A	g.18133A>T	p.D181V	G6PD	rs5030872	154534440
778550	105	c.544C>T	g.154534438G>A	g.18135C>T	p.R182W	G6PD	rs267606836	154534438
778552	105	c.563C>T	g.154534419G>A	g.18154C>T	p.S188F	G6PD	rs5030868	154534419
778553	105	c.573C>G	g.154534409G>C	g.18164C>G	p.F191L	G6PD	\N	154534409
778554	105	c.592C>T	g.154534390G>A	g.18183C>T	p.R198C	G6PD	rs137852330	154534390
2406824	67	c.593G>A;c.593G>C	g.154534389C>T;g.154534389C>G	g.18184G>A;g.18184G>C	p.R198H;p.R198P	G6PD	rs137852332	154534389
778556	105	c.595A>G	g.154534387T>C	g.18186A>G	p.I199V	G6PD	rs781865768	154534387
778557	105	c.634A>G	g.154534348T>C	g.18225A>G	p.M212V	G6PD	rs782754619	154534348
778558	105	c.637G>T	g.154534345C>A	g.18228G>T	p.V213L	G6PD	rs137852326	154534345
778559	105	c.648T>G	g.154534157A>C	g.18416T>G	p.F216L	G6PD	rs137852319	154534157
778560	105	c.679C>T	g.154534126G>A	g.18447C>T	p.R227W	G6PD	\N	154534126
778562	105	c.683_685delACA	g.154534120_154534122delTGT	g.18451_18453delACA	p.N229del	G6PD	\N	154534120
778563	105	c.695G>A	g.154534110C>T	g.18463G>A	p.C232Y	G6PD	\N	154534110
3685108	43	c.6671G>A	g.38496416G>A	g.67717G>A	p.R2224H	RYR1	rs537994744	38496416
3685109	43	c.6670C>T	g.38496415C>T	g.67716C>T	p.R2224C	RYR1	rs199870223	38496415
3685169	43	c.8005G>A	g.38504298G>A	g.75599G>A	p.E2669K	RYR1	\N	38504298
3685174	43	c.8198G>A	g.38504878G>A	g.76179G>A	p.G2733D	RYR1	rs193922828	38504878
3685175	43	c.8290G>A	g.38505061G>A	g.76362G>A	p.E2764K	RYR1	rs193922829	38505061
3685176	43	c.8327C>T	g.38505325C>T	g.76626C>T	p.S2776F	RYR1	rs147707463	38505325
3685177	43	c.8360C>G	g.38505358C>G	g.76659C>G	p.T2787S	RYR1	rs35180584	38505358
3685214	43	c.11132C>T	g.38529048C>T	g.100349C>T	p.T3711M	RYR1	rs375915752	38529048
3685215	43	c.11266C>G	g.38534726C>G	g.106027C>G	p.Q3756E	RYR1	rs4802584	38534726
3685216	43	c.11315G>A	g.38534775G>A	g.106076G>A	p.R3772Q	RYR1	rs193922839	38534775
3685217	43	c.11314C>T	g.38534774C>T	g.106075C>T	p.R3772W	RYR1	rs763112609	38534774
3685218	43	c.11416G>A	g.38535197G>A	g.106498G>A	p.G3806R	RYR1	rs111565359	38535197
3685219	43	c.11518G>A	g.38535998G>A	g.107299G>A	p.V3840I	RYR1	rs140616359	38535998
3685220	43	c.11708G>A	g.38543365G>A	g.114666G>A	p.R3903Q	RYR1	rs148399313	38543365
3685221	43	c.11723A>T	g.38543380A>T	g.114681A>T	p.N3908I	RYR1	\N	38543380
3685222	43	c.11748T>G	g.38543405T>G	g.114706T>G	p.I3916M	RYR1	rs193922840	38543405
3685223	43	c.11798A>G	g.38543551A>G	g.114852A>G	p.Y3933C	RYR1	rs147136339	38543551
3685224	43	c.11813G>A	g.38543566G>A	g.114867G>A	p.G3938D	RYR1	\N	38543566
3685225	43	c.11947C>T	g.38543810C>T	g.115111C>T	p.R3983C	RYR1	\N	38543810
3685226	43	c.11953T>C	g.38543816T>C	g.115117T>C	p.W3985R	RYR1	rs118204422	38543816
3685227	43	c.11958C>G	g.38543821C>G	g.115122C>G	p.D3986E	RYR1	rs193922842	38543821
779140	105	c.11969G>T	g.38543832G>T	g.115133G>T	p.G3990V	RYR1	rs193922843	38543832
3685229	43	c.12028G>A	g.38546460G>A	g.117761G>A	p.E4010K	RYR1	rs755088027	38546460
3685230	43	c.12064A>G	g.38546496A>G	g.117797A>G	p.M4022V	RYR1	rs773040531	38546496
3685231	43	c.12115A>T	g.38548253A>T	g.119554A>T	p.I4039F	RYR1	\N	38548253
3685232	43	c.12121C>T	g.38548259C>T	g.119560C>T	p.R4041W	RYR1	rs144685735	38548259
3685233	43	c.12149C>A	g.38548287C>A	g.119588C>A	p.S4050Y	RYR1	rs193922844	38548287
777275	105	G178R	g.117534318G>A	g.73535G>A	p.G178R	CFTR	rs80282562	117534318
777276	105	E193K	g.117534363G>A	g.73580G>A	p.E193K	CFTR	rs397508759	117534363
777277	105	L206W	g.117535285T>G	g.74502T>G	p.L206W	CFTR	rs121908752	117535285
777279	105	R352Q	g.117540285G>A	g.79502G>A	p.R352Q	CFTR	rs121908753	117540285
777280	105	A455E/ Class: V	g.117548795C>A	g.88012C>A	p.A455E	CFTR	rs74551128	117548795
777284	105	G551S	g.117587805G>A	g.127022G>A	p.G551S	CFTR	rs121909013	117587805
777285	105	G551D/Class: III	g.117587806G>A	g.127023G>A	p.G551D	CFTR	rs75527207	117587806
777286	105	D579G	g.117590409A>G	g.129626A>G	p.D579G	CFTR	rs397508288	117590409
777287	105	E831X	g.117594930G>T	g.134147G>T	p.E831X	CFTR	rs397508387	117594930
777288	105	S945L	g.117603708C>T	g.142925C>T	p.S945L	CFTR	rs397508442	117603708
777289	105	S977F	g.117606695C>T	g.145912C>T	p.S977F	CFTR	rs141033578	117606695
777496	105	-806C>T	g.94761900C>T	g.4220C>T	p.expression	CYP2C19	rs12248560	94761900
777510	105	12718A>C	g.94775423A>C	g.17743A>C	p.E122A	CYP2C19	rs17885179	94775423
3819813	39	4173C>T	g.42126619G>A	g.9192C>T	\N	CYP2D6	rs28371736	42126619
3819812	39	4170T>C	g.42126622A>G	g.9189T>C	\N	CYP2D6	rs747998333	42126622
3819809	39	4167T>C	g.42126625A>G	g.9186T>C	\N	CYP2D6	\N	42126625
3819802	39	4134T>C	g.42126658A>G	g.9153T>C	\N	CYP2D6	rs1135836	42126658
3819798	39	4125G>C	g.42126667C>G	g.9144G>C	\N	CYP2D6	rs1135832	42126667
778493	105	c.25C>T	g.154546131G>A	g.6442C>T	p.R9W	G6PD	\N	154546131
778494	105	c.34G>T	g.154546122C>A	g.6451G>T	p.V12L	G6PD	\N	154546122
778495	105	c.40G>A	g.154546116C>T	g.6457G>A	p.G14R	G6PD	\N	154546116
778496	105	c.95A>G	g.154546061T>C	g.6512A>G	p.H32R	G6PD	rs137852340	154546061
778497	105	c.99A>G	g.154546057T>C	g.6516A>G	p.I33M	G6PD	\N	154546057
778498	105	c.103_105delATC	g.154546051_154546053delGAT	g.6520_6522delATC	p.I35del	G6PD	rs137852338	154546051
778499	105	c.110T>C	g.154546046A>G	g.6527T>C	p.M37T	G6PD	\N	154546046
778500	105	c.130G>A	g.154536169C>T	g.16404G>A	p.A44T	G6PD	\N	154536169
778501	105	c.131C>G	g.154536168G>C	g.16405C>G	p.A44G	G6PD	rs78478128	154536168
778502	105	c.143T>C	g.154536156A>G	g.16417T>C	p.I48T	G6PD	rs76645461	154536156
778503	105	c.148C>T	g.154536151G>A	g.16422C>T	p.P50S	G6PD	\N	154536151
778564	105	c.703C>T	g.154534102G>A	g.18471C>T	p.L235F	G6PD	rs782757170	154534102
778565	105	c.713A>G	g.154534092T>C	g.18481A>G	p.K238R	G6PD	\N	154534092
778567	105	c.769C>G	g.154534036G>C	g.18537C>G	p.R257G	G6PD	\N	154534036
778568	105	c.806G>A	g.154533634C>T	g.18939G>A	p.C269Y	G6PD	rs137852346	154533634
778569	105	c.811G>C	g.154533629C>G	g.18944G>C	p.V271L	G6PD	\N	154533629
778570	105	c.820G>A	g.154533620C>T	g.18953G>A	p.E274K	G6PD	\N	154533620
778571	105	c.821A>T	g.154533619T>A	g.18954A>T	p.E274V	G6PD	\N	154533619
778572	105	c.825G>C	g.154533615C>G	g.18958G>C	p.K275N	G6PD	\N	154533615
778573	105	c.826C>T	g.154533614G>A	g.18959C>T	p.P276S	G6PD	\N	154533614
778574	105	c.832T>C	g.154533608A>G	g.18965T>C	p.S278P	G6PD	\N	154533608
778575	105	c.833C>T	g.154533607G>A	g.18966C>T	p.S278F	G6PD	\N	154533607
2406846	67	c.844G>T;c.844G>C	g.154533596C>A;g.154533596C>G	g.18977G>T;g.18977G>C	p.D282H;p.D282Y	G6PD	rs137852318	154533596
778578	105	c.848A>G	g.154533592T>C	g.18981A>G	p.D283G	G6PD	\N	154533592
778579	105	c.849C>A	g.154533591G>T	g.18982C>A	p.D283E	G6PD	\N	154533591
778580	105	c.851T>C	g.154533589A>G	g.18984T>C	p.V284A	G6PD	\N	154533589
778581	105	c.853C>T	g.154533587G>A	g.18986C>T	p.R285C	G6PD	\N	154533587
778582	105	c.854G>A	g.154533586C>T	g.18987G>A	p.R285H	G6PD	rs74575103	154533586
778583	105	c.871G>A	g.154533122C>T	g.19451G>A	p.V291M	G6PD	rs137852327	154533122
778584	105	c.910G>T	g.154533083C>A	g.19490G>T	p.V303F	G6PD	\N	154533083
778585	105	c.916G>A	g.154533077C>T	g.19496G>A	p.G306S	G6PD	\N	154533077
778586	105	c.921G>C	g.154533072C>G	g.19501G>C	p.Q307H	G6PD	\N	154533072
778587	105	c.929G>A	g.154533064C>T	g.19509G>A	p.G310E	G6PD	\N	154533064
778588	105	c.949G>A	g.154533044C>T	g.19529G>A	p.E317K	G6PD	rs137852339	154533044
778590	105	c.962G>A	g.154533031C>T	g.19542G>A	p.G321E	G6PD	\N	154533031
778591	105	c.964T>C	g.154533029A>G	g.19544T>C	p.Y322H	G6PD	rs137852347	154533029
778592	105	c.968T>C	g.154533025A>G	g.19548T>C	p.L323P	G6PD	rs76723693	154533025
778593	105	c.977C>A	g.154533016G>T	g.19557C>A	p.P326H	G6PD	\N	154533016
778594	105	c.989G>A	g.154533004C>T	g.19569G>A	p.R330H	G6PD	\N	154533004
778598	105	c.1006A>G	g.154532987T>C	g.19586A>G	p.T336A	G6PD	\N	154532987
778599	105	c.1024C>T	g.154532969G>A	g.19604C>T	p.L342F	G6PD	rs137852342	154532969
778600	105	c.1037A>T	g.154532956T>A	g.19617A>T	p.N346I	G6PD	rs398123544	154532956
778601	105	c.1048G>C	g.154532945C>G	g.19628G>C	p.D350H	G6PD	rs34193178	154532945
778602	105	c.1052G>T	g.154532802C>A	g.19771G>T	p.G351V	G6PD	\N	154532802
778603	105	c.1057C>T	g.154532797G>A	g.19776C>T	p.P353S	G6PD	rs137852333	154532797
778604	105	c.1081G>A	g.154532773C>T	g.19800G>A	p.A361T	G6PD	\N	154532773
778605	105	c.1082C>T	g.154532772G>A	g.19801C>T	p.A361V	G6PD	rs137852345	154532772
778608	105	c.1096A>G	g.154532758T>C	g.19815A>G	p.K366E	G6PD	\N	154532758
778609	105	c.1132G>A	g.154532722C>T	g.19851G>A	p.G378S	G6PD	rs371489738	154532722
778610	105	c.1138A>G	g.154532716T>C	g.19857A>G	p.I380V	G6PD	\N	154532716
778611	105	c.1139T>C	g.154532715A>G	g.19858T>C	p.I380T	G6PD	\N	154532715
778612	105	c.1141T>C	g.154532713A>G	g.19860T>C	p.F381L	G6PD	\N	154532713
778613	105	c.1153T>C	g.154532701A>G	g.19872T>C	p.C385R	G6PD	rs137852322	154532701
778618	105	c.1160G>A	g.154532694C>T	g.19879G>A	p.R387H	G6PD	rs137852321	154532694
778619	105	c.1162A>G	g.154532692T>C	g.19881A>G	p.N388D	G6PD	\N	154532692
3685023	43	c.947G>T	g.38448501G>T	g.19802G>T	p.R316L	RYR1	rs193922761	38448501
3685196	43	c.9848G>A	g.38517521G>A	g.88822G>A	p.R3283Q	RYR1	rs757753317	38517521
777512	105	12784G>A	g.94775489G>A	g.17809G>A	p.R144H	CYP2C19	rs17884712	94775489
777648	105	42568C>A	g.94981250C>A	g.48093C>A	p.S343R	CYP2C9	rs750820937	94981250
1932813	76	42576C>T	g.94981258C>T	g.48101C>T	p.P346L	CYP2C9	rs1297714792	94981258
777649	105	42599G>A	g.94981281G>A	g.48124G>A	p.E354K	CYP2C9	rs749060448	94981281
777650	105	42614A>C	g.94981296A>C	g.48139A>C	p.I359L	CYP2C9	rs1057910	94981296
777652	105	42619C>G	g.94981301C>G	g.48144C>G	p.D360E	CYP2C9	rs28371686	94981301
777653	105	42620C>A	g.94981302C>A	g.48145C>A	p.L361I	CYP2C9	rs1250577724	94981302
777654	105	42623C>G	g.94981305C>G	g.48148C>G	p.L362V	CYP2C9	rs578144976	94981305
777933	105	4181G>C	g.42126611C>G	g.9200G>C	p.S486T	CYP2D6	rs1135840	42126611
777932	105	4169C>G	g.42126623G>C	g.9188C>G	p.A482G	CYP2D6	rs75467367	42126623
777931	105	4168G>A	g.42126624C>T	g.9187G>A	p.A482T	CYP2D6	rs74478221	42126624
777930	105	4165T>G	g.42126627A>C	g.9184T>G	p.F481V	CYP2D6	\N	42126627
777929	105	4159G>C	g.42126633C>G	g.9178G>C	p.G479R	CYP2D6	rs1135837	42126633
777928	105	4158T>G	g.42126634A>C	g.9177T>G	p.H478Q	CYP2D6	\N	42126634
777926	105	4156C>T	g.42126636G>A	g.9175C>T	p.H478Y	CYP2D6	rs28371735	42126636
777858	105	1914G>T	g.42128878C>A	g.6933G>T	p.C191F	CYP2D6	rs747884067	42128878
777857	105	1913T>C	g.42128879A>G	g.6932T>C	p.C191R	CYP2D6	rs2146937045	42128879
778244	105	c.46C>G	g.97883368G>C	g.42692C>G	p.L16V	DPYD	rs150036960	97883368
778540	105	c.488G>A	g.154534494C>T	g.18079G>A	p.G163D	G6PD	\N	154534494
778541	105	c.493A>G	g.154534489T>C	g.18084A>G	p.N165D	G6PD	rs137852331	154534489
778542	105	c.496C>T	g.154534486G>A	g.18087C>T	p.R166C	G6PD	\N	154534486
778543	105	c.497G>A	g.154534485C>T	g.18088G>A	p.R166H	G6PD	\N	154534485
778544	105	c.514C>T	g.154534468G>A	g.18105C>T	p.P172S	G6PD	\N	154534468
778545	105	c.517T>C	g.154534465A>G	g.18108T>C	p.F173L	G6PD	rs137852343	154534465
778546	105	c.519C>G	g.154534463G>C	g.18110C>G	p.F173L	G6PD	\N	154534463
778547	105	c.527A>G	g.154534455T>C	g.18118A>G	p.D176G	G6PD	\N	154534455
778615	105	c.1155C>G	g.154532699G>C	g.19874C>G	p.C385W	G6PD	\N	154532699
778616	105	c.1156A>G	g.154532698T>C	g.19875A>G	p.K386E	G6PD	rs137852320	154532698
778620	105	c.1166A>G	g.154532688T>C	g.19885A>G	p.E389G	G6PD	\N	154532688
778621	105	c.1175T>C	g.154532679A>G	g.19894T>C	p.I392T	G6PD	\N	154532679
778622	105	c.1177C>G	g.154532677G>C	g.19896C>G	p.R393G	G6PD	\N	154532677
778623	105	c.1178G>A	g.154532676C>T	g.19897G>A	p.R393H	G6PD	rs137852316	154532676
778632	105	c.1226C>G	g.154532628G>C	g.19945C>G	p.P409R	G6PD	\N	154532628
778635	105	c.1231A>G	g.154532623T>C	g.19950A>G	p.M411V	G6PD	\N	154532623
778636	105	c.1246G>A	g.154532608C>T	g.19965G>A	p.E416K	G6PD	\N	154532608
778637	105	c.1264C>G	g.154532590G>C	g.19983C>G	p.L422V	G6PD	\N	154532590
778638	105	c.1284C>A	g.154532570G>T	g.20003C>A	p.Y428X	G6PD	\N	154532570
778639	105	c.1291G>A	g.154532459C>T	g.20114G>A	p.V431M	G6PD	rs782098548	154532459
778640	105	c.1292T>G	g.154532458A>C	g.20115T>G	p.V431G	G6PD	\N	154532458
778641	105	c.1311C>T	g.154532439G>A	g.20134C>T	p.Y437Y	G6PD	rs2230037	154532439
778642	105	c.1316G>C	g.154532434C>G	g.20139G>C	p.Arg439Pro	G6PD	rs137852337	154532434
778643	105	c.1318C>T	g.154532432G>A	g.20141C>T	p.L440F	G6PD	\N	154532432
778644	105	c.1339G>A	g.154532411C>T	g.20162G>A	p.G447R	G6PD	rs137852317	154532411
778645	105	c.1342A>G	g.154532408T>C	g.20165A>G	p.S448G	G6PD	\N	154532408
778646	105	c.1347G>C	g.154532403C>G	g.20170G>C	p.Q449H	G6PD	\N	154532403
778647	105	c.1358T>A	g.154532392A>T	g.20181T>A	p.V453E	G6PD	\N	154532392
778648	105	c.1360C>T	g.154532390G>A	g.20183C>T	p.R454C	G6PD	rs398123546	154532390
778649	105	c.1361G>A	g.154532389C>T	g.20184G>A	p.R454H	G6PD	rs137852324	154532389
778650	105	c.1366G>C	g.154532279C>G	g.20294G>C	p.D456H	G6PD	\N	154532279
778651	105	c.1367A>T	g.154532278T>A	g.20295A>T	p.D456V	G6PD	\N	154532278
778659	105	c.1442C>G	g.154532203G>C	g.20370C>G	p.P481R	G6PD	rs137852348	154532203
778660	105	c.1462G>A	g.154532086C>T	g.20487G>A	p.G488S	G6PD	\N	154532086
778661	105	c.1463G>T	g.154532085C>A	g.20488G>T	p.G488V	G6PD	\N	154532085
778662	105	c.1465C>T	g.154532083G>A	g.20490C>T	p.P489S	G6PD	\N	154532083
778663	105	c.1466C>T	g.154532082G>A	g.20491C>T	p.P489L	G6PD	\N	154532082
778664	105	c.1488_1490delGAA	g.154532058_154532060delTTC	g.20513_20515delGAA	p.K497del	G6PD	\N	154532058
778665	105	c.1502T>G	g.154532046A>C	g.20527T>G	p.F501C	G6PD	\N	154532046
828072	104	669T>C	m.669T>C	\N	\N	MT-RNR1	\N	669
3685234	43	c.12242C>T	g.38548380C>T	g.119681C>T	p.T4081M	RYR1	rs373406011	38548380
3685235	43	c.12310G>C	g.38561140G>C	g.132441G>C	p.G4104R	RYR1	\N	38561140
3685236	43	c.12355A>T	g.38561185A>T	g.132486A>T	p.N4119Y	RYR1	rs193922848	38561185
3685237	43	c.12383C>T	g.38561213C>T	g.132514C>T	p.A4128V	RYR1	\N	38561213
3685238	43	c.12398A>G	g.38561228A>G	g.132529A>G	p.E4133G	RYR1	rs201321695	38561228
3685239	43	c.12406C>A	g.38561236C>A	g.132537C>A	p.R4136S	RYR1	rs193922849	38561236
3685240	43	c.12413T>C	g.38561243T>C	g.132544T>C	p.I4138T	RYR1	rs193922850	38561243
3685241	43	c.12532G>A	g.38561362G>A	g.132663G>A	p.G4178S	RYR1	\N	38561362
3685242	43	c.12533G>T	g.38561363G>T	g.132664G>T	p.G4178V	RYR1	\N	38561363
3685243	43	c.12553G>A	g.38561383G>A	g.132684G>A	p.A4185T	RYR1	rs151119428	38561383
3685244	43	c.12689T>G	g.38565023T>G	g.136324T>G	p.M4230R	RYR1	\N	38565023
3685246	43	c.12848A>T	g.38565182A>T	g.136483A>T	p.E4283V	RYR1	rs193922853	38565182
3685247	43	c.12881C>T	g.38565215C>T	g.136516C>T	p.T4294M	RYR1	rs587784372	38565215
3685248	43	c.12884C>T	g.38565218C>T	g.136519C>T	p.A4295V	RYR1	rs193922855	38565218
3685249	43	c.13505A>G	g.38566978A>G	g.138279A>G	p.E4502G	RYR1	rs139647387	38566978
3685250	43	c.13513G>C	g.38566986G>C	g.138287G>C	p.D4505H	RYR1	rs150396398	38566986
2406923	67	c.1387C>A;c.1387C>T	g.154532258G>T;g.154532258G>A	g.20315C>A;g.20315C>T	p.R463S;p.R463C	G6PD	\N	154532258
778655	105	c.1381G>A	g.154532264C>T	g.20309G>A	p.A461T	G6PD	rs782608284	154532264
778656	105	c.1388G>A	g.154532257C>T	g.20316G>A	p.R463H	G6PD	rs72554664	154532257
778657	105	c.1400C>G	g.154532245G>C	g.20328C>G	p.P467R	G6PD	rs137852344	154532245
778658	105	c.1414A>C	g.154532231T>G	g.20342A>C	p.I472L	G6PD	\N	154532231
3685251	43	c.13673G>A	g.38570620G>A	g.141921G>A	p.R4558Q	RYR1	rs118192130	38570620
3685252	43	c.13672C>T	g.38570619C>T	g.141920C>T	p.R4558W	RYR1	rs771741606	38570619
3685253	43	c.13702C>G	g.38570649C>G	g.141950C>G	p.L4568V	RYR1	\N	38570649
3685254	43	c.13760C>T	g.38572032C>T	g.143333C>T	p.P4587L	RYR1	rs143520367	38572032
3685255	43	c.13913G>A	g.38572185G>A	g.143486G>A	p.G4638D	RYR1	rs118192135	38572185
3685256	43	c.13918A>G	g.38572190A>G	g.143491A>G	p.M4640V	RYR1	rs756850145	38572190
3685257	43	c.13934G>A	g.38572206G>A	g.143507G>A	p.R4645Q	RYR1	rs193922860	38572206
3685258	43	c.13990T>C	g.38572262T>C	g.143563T>C	p.C4664R	RYR1	rs759500310	38572262
3685260	43	c.14002C>T	g.38573180C>T	g.144481C>T	p.P4668S	RYR1	rs193922863	38573180
3685261	43	c.14051T>C	g.38573229T>C	g.144530T>C	p.F4684S	RYR1	rs193922864	38573229
3685262	43	c.14126C>T	g.38573304C>T	g.144605C>T	p.T4709M	RYR1	rs118192140	38573304
3685263	43	c.14168G>A	g.38575957G>A	g.147258G>A	p.R4723H	RYR1	rs200766617	38575957
3685264	43	c.14186A>C	g.38577931A>C	g.149232A>C	p.H4729P	RYR1	\N	38577931
3685265	43	c.14197T>G	g.38577942T>G	g.149243T>G	p.Y4733D	RYR1	rs193922865	38577942
3685266	43	c.14201G>A	g.38577946G>A	g.149247G>A	p.G4734E	RYR1	rs193922866	38577946
3685267	43	c.14209C>T	g.38577954C>T	g.149255C>T	p.R4737W	RYR1	rs193922867	38577954
3685268	43	c.14210G>A	g.38577955G>A	g.149256G>A	p.R4737Q	RYR1	rs193922868	38577955
3685269	43	c.14270G>A	g.38578015G>A	g.149316G>A	p.R4757H	RYR1	rs768360593	38578015
779141	105	c.14387A>G	g.38580004A>G	g.151305A>G	p.Y4796C	RYR1	rs118192167	38580004
3685271	43	c.14422_14423delinsAA	g.38580039_38580040delinsAA	g.151340_151341delinsAA	p.F4808N	RYR1	\N	38580039
3685272	43	c.14424C>A	g.38580041C>A	g.151342C>A	p.F4808L	RYR1	\N	38580041
3685273	43	c.14449A>T	g.38580066A>T	g.151367A>T	p.I4817F	RYR1	rs143988412	38580066
3685274	43	c.14458G>A; c.14458G>T	g.38580075G>A; g.38580075G>T	g.151376G>A; g.151376G>T	p.G4820R; p.G4820W	RYR1	rs193922873	38580075
3685275	43	c.14471T>C	g.38580088T>C	g.151389T>C	p.L4824P	RYR1	rs193922874	38580088
779142	105	c.14477C>T	g.38580094C>T	g.151395C>T	p.T4826I	RYR1	rs121918595	38580094
779143	105	c.14497C>T	g.38580114C>T	g.151415C>T	p.H4833Y	RYR1	rs193922876	38580114
3685284	43	c.14558C>T	g.38580416C>T	g.151717C>T	p.T4853I	RYR1	\N	38580416
3685285	43	c.14567C>G	g.38580425C>G	g.151726C>G	p.A4856G	RYR1	rs193922880	38580425
779146	105	c.14582G>A	g.38580440G>A	g.151741G>A	p.R4861H	RYR1	rs63749869	38580440
3685287	43	c.14581C>T	g.38580439C>T	g.151740C>T	p.R4861C	RYR1	rs118192181	38580439
3685288	43	c.14627A>G	g.38580485A>G	g.151786A>G	p.K4876R	RYR1	rs113210953	38580485
3685289	43	c.14639T>C	g.38580497T>C	g.151798T>C	p.M4880T	RYR1	rs193922883	38580497
3685290	43	c.14678G>A	g.38584974G>A	g.156275G>A	p.R4893Q	RYR1	rs118192151	38584974
3685291	43	c.14680G>A	g.38584976G>A	g.156277G>A	p.A4894T	RYR1	rs193922888	38584976
779147	105	c.14693T>C	g.38584989T>C	g.156290T>C	p.I4898T	RYR1	rs118192170	38584989
3685293	43	c.14782A>G	g.38585078A>G	g.156379A>G	p.I4928V	RYR1	\N	38585078
3685294	43	c.14803G>A	g.38585099G>A	g.156400G>A	p.G4935S	RYR1	\N	38585099
3685295	43	c.14813T>C	g.38585947T>C	g.157248T>C	p.I4938T	RYR1	rs111657878	38585947
3685296	43	c.14814C>G	g.38585948C>G	g.157249C>G	p.I4938M	RYR1	rs118192159	38585948
3685299	43	c.14825G>T	g.38585959G>T	g.157260G>T	p.G4942V	RYR1	rs193922896	38585959
3685300	43	c.14879T>A	g.38586101T>A	g.157402T>A	p.F4960Y	RYR1	rs193922898	38586101
3685301	43	c.14918C>T	g.38586140C>T	g.157441C>T	p.P4973L	RYR1	rs146876145	38586140
3685302	43	c.14968A>G	g.38586190A>G	g.157491A>G	p.M4990V	RYR1	\N	38586190
3685303	43	c.15059G>C	g.38587362G>C	g.158663G>C	p.W5020S	RYR1	\N	38587362
3685304	43	c.15060G>C	g.38587363G>C	g.158664G>C	p.W5020C	RYR1	\N	38587363
3685305	43	c.14364+1G>T	g.38578205G>T	g.149506G>T	\N	RYR1	\N	38578205
779247	105	31160C>T	g.21172734C>T	g.46541C>T	p.R57W	SLCO1B1	rs139257324	21172734
779248	105	31202G>A	g.21172776G>A	g.46583G>A	p.G71R	SLCO1B1	rs373327528	21172776
779249	105	31208T>C	g.21172782T>C	g.46589T>C	p.F73L	SLCO1B1	rs56101265	21172782
779349	105	1A>G	g.18149127T>C	g.11017A>G	p.M1V	TPMT	rs9333569	18149127
779350	105	2T>C	g.18149126A>G	g.11018T>C	p.M1T	TPMT	rs267607275	18149126
779352	105	95_96insA	g.18149032_18149033insT	g.11111_11112insA	p.K32KfsX58	TPMT	rs759836180	18149032
779353	105	106G>A	g.18149022C>T	g.11122G>A	p.G36S	TPMT	rs750424422	18149022
779354	105	124C>G	g.18149004G>C	g.11140C>G	p.Q42E	TPMT	\N	18149004
779355	105	146T>C	g.18147910A>G	g.12234T>C	p.L49S	TPMT	rs72552740	18147910
779356	105	200T>C	g.18147856A>G	g.12288T>C	p.F67S	TPMT	\N	18147856
779357	105	205C>G	g.18147851G>C	g.12293C>G	p.L69V	TPMT	rs200591577	18147851
779358	105	211G>A	g.18147845C>T	g.12299G>A	p.G71R	TPMT	rs777686348	18147845
779359	105	218C>T	g.18147838G>A	g.12306C>T	p.A73V	TPMT	rs281874771	18147838
779360	105	234G>T	g.18143728C>A	g.16416G>T	p.W78C	TPMT	rs1256618794	18143728
779361	105	238G>C	g.18143724C>G	g.16420G>C	p.A80P	TPMT	rs1800462	18143724
779362	105	244C>T	g.18143718G>A	g.16426C>T	p.R82W	TPMT	rs111901354	18143718
779363	105	262G>A	g.18143700C>T	g.16444G>A	p.G88S	TPMT	rs753545734	18143700
779364	105	319T>G	g.18143643A>C	g.16501T>G	p.Y107D	TPMT	\N	18143643
779366	105	349G>C	g.18143613C>G	g.16531G>C	p.G117R	TPMT	\N	18143613
779367	105	356A>C	g.18143606T>G	g.16538A>C	p.K119T	TPMT	rs151149760	18143606
779368	105	365A>C	g.18143597T>G	g.16547A>C	p.K122T	TPMT	\N	18143597
779369	105	374C>T	g.18139710G>A	g.20434C>T	p.S125L	TPMT	rs200220210	18139710
779040	105	-1595G>A	g.39248147C>T	g.1825G>A	unknown (upstream)	IFNL3	rs12979860	39248147
3685278	43	c.14510delA	g.38580127delA	g.151428delA	p.Q4837Rfs*3	RYR1	rs193922877	38580127
3685279	43	c.14509C>G	g.38580126C>G	g.151427C>G	p.Q4837E	RYR1	\N	38580126
779144	105	c.14512C>G	g.38580370C>G	g.151671C>G	p.L4838V	RYR1	rs193922878	38580370
3685281	43	c.14524G>A	g.38580382G>A	g.151683G>A	p.V4842M	RYR1	rs193922879	38580382
3685282	43	c.14539G>C	g.38580397G>C	g.151698G>C	p.V4847L	RYR1	\N	38580397
779145	105	c.14545G>A	g.38580403G>A	g.151704G>A	p.V4849I	RYR1	rs118192168	38580403
779370	105	395G>A	g.18139689C>T	g.20455G>A	p.C132Y	TPMT	rs72552738	18139689
779371	105	430G>C	g.18139027C>G	g.21117G>C	p.G144R	TPMT	rs72552737	18139027
779372	105	460G>A	g.18138997C>T	g.21147G>A	p.A154T	TPMT	rs1800460	18138997
779373	105	487C>T	g.18138970G>A	g.21174C>T	p.R163C	TPMT	rs112339338	18138970
779374	105	488G>A; 488G>C	g.18138969C>T; g.18138969C>G	g.21175G>A; g.21175G>C	p.R163H; p.R163P	TPMT	rs144041067	18138969
779375	105	495-1G>A	g.18133890C>T	g.26254G>A	\N	TPMT	rs9333570	18133890
779376	105	497A>G	g.18133887T>C	g.26257A>G	p.Y166C	TPMT	rs201695576	18133887
779377	105	500C>G	g.18133884G>C	g.26260C>G	p.A167G	TPMT	rs74423290	18133884
779380	105	539A>T	g.18133845T>A	g.26299A>T	p.Y180F	TPMT	rs75543815	18133845
779381	105	595G>A	g.18132163C>T	g.27981G>A	p.V199I	TPMT	\N	18132163
779382	105	611T>C	g.18132147A>G	g.27997T>C	p.I204T	TPMT	rs79901429	18132147
779383	105	622T>C	g.18132136A>G	g.28008T>C	p.F208L	TPMT	rs72556347	18132136
779384	105	626-1G>A	g.18130781C>T	g.29363G>A	\N	TPMT	rs1800584	18130781
779385	105	634T>C	g.18130772A>G	g.29372T>C	p.C212R	TPMT	rs377085266	18130772
779386	105	644G>A	g.18130762C>T	g.29382G>A	p.R215H	TPMT	rs56161402	18130762
779387	105	648T>A	g.18130758A>T	g.29386T>A	p.C216X	TPMT	rs398122996	18130758
779388	105	677G>A	g.18130729C>T	g.29415G>A	p.R226Q	TPMT	rs139392616	18130729
779389	105	681T>G	g.18130725A>C	g.29419T>G	p.H227Q	TPMT	rs72552736	18130725
779390	105	712A>G	g.18130694T>C	g.29450A>G	p.K238E	TPMT	rs150900439	18130694
779391	105	719A>G;719A>C	g.18130687T>C; g.18130687T>G	g.29457A>G; g.29457A>C	p.Y240C; p.Y240S	TPMT	rs1142345	18130687
779484	105	-364C>T	g.233759924C>T	g.175181C>T	5' Flanking	UGT1A1	rs887829	233759924
1000510	96	CA(TA)5TAA CA(TA)6TAA CA(TA)7TAA CA(TA)8TAA	g.233760235TA[6]; g.233760235TA[7]; g.233760235TA[8]; g.233760235TA[9]	g.175492TA[6]; g.175492TA[7]; g.175492TA[8]; g.175492TA[9]	5' Flanking	UGT1A1	rs3064744	233760235
779486	105	211G>A	g.233760498G>A	g.175755G>A	p.G71R	UGT1A1	rs4148323	233760498
779487	105	686C>A	g.233760973C>A	g.176230C>A	p.P229Q	UGT1A1	rs35350960	233760973
779506	105	-1639G>A	g.31096368C>T	g.3588G>A	5' region	VKORC1	rs9923231	31096368
777260	105	c.520C>T	g.201091993G>A	g.25574C>T	p.R174W	CACNA1S	rs772226819	201091993
777261	105	c.3257G>A	g.201060815C>T	g.56752G>A	p.R1086H	CACNA1S	rs1800559	201060815
8101108	1	27124C>G	g.99652773G>C	g.32226C>G	p.P345A	CYP3A5	rs762725013	99652773
8101112	1	3755G>T	g.99676142C>A	g.8857G>T	p.L46F	CYP3A5	rs150999943	99676142
7850730	3	676C>T	g.18130730G>A	g.29414C>T	p.R226X	TPMT	rs761990479	18130730
777269	105	P67L	g.117509069C>T	g.48286C>T	p.P67L	CFTR	rs368505753	117509069
777270	105	R74W	g.117509089C>T	g.48306C>T	p.R74W	CFTR	rs115545701	117509089
6355113	14	R75Q	g.117509093G>A	g.48310G>A	p.R75Q	CFTR	rs1800076	117509093
777271	105	D110E	g.117530955C>A	g.70172C>A	p.D110E	CFTR	rs397508537	117530955
6355116	14	R117C; R117G	g.117530974C>T; g.117530974C>G	g.70191C>T; g.70191C>G	p.R117C; p.R117G	CFTR	rs77834169	117530974
6355117	14	R117H/ Class: IV; R117L; R117P	g.117530975G>A; g.117530975G>T; g.117530975G>C	g.70192G>A; g.70192G>T; g.70192G>C	p.R117H; p.R117L; p.R117P	CFTR	rs78655421	117530975
6355125	14	D192G	g.117534361A>G	g.73578A>G	p.D192G	CFTR	rs397508758	117534361
777304	105	2789+5G->A/ Class: V	g.117602868G>A	g.142085G>A	Intronic	CFTR	rs80224560	117602868
6355168	14	M952I(G>A); M952I(G>C); M952I(G>T)	g.117603730G>A; g.117603730G>C; g.117603730G>T	g.142947G>A; g.142947G>C; g.142947G>T	p.M952I	CFTR	rs151048781	117603730
6355172	14	L997F(G>C); L997F(G>T)	g.117610521G>C; g.117610521G>T	g.149738G>C; g.149738G>T	p.L997F	CFTR	rs1800111	117610521
777295	105	R1070W	g.117611649C>T	g.150866C>T	p.R1070W	CFTR	rs202179988	117611649
778245	105	c.61C>T	g.97883353G>A	g.42707C>T	p.R21X	DPYD	rs72549310	97883353
778256	105	c.601A>C	g.97699430T>G	g.226630A>C	p.S201R	DPYD	rs72549308	97699430
778283	105	c.1484A>G	g.97549600T>C	g.376460A>G	p.D495G	DPYD	rs111858276	97549600
778288	105	c.1615G>A	g.97515851C>T	g.410209G>A	p.G539R	DPYD	rs142619737	97515851
778317	105	c.2872A>G	g.97082365T>C	g.843695A>G	p.K958E	DPYD	rs141044036	97082365
778322	105	c.2977C>T	g.97079077G>A	g.846983C>T	p.L993F	DPYD	rs202144771	97079077
777392	105	85C>A	g.40991390C>A	g.5092C>A	p.R29S	CYP2B6	rs33926104	40991390
2899055	58	21161G>A	g.41012466G>A	g.26168G>A	p.R378Q	CYP2B6	rs200458614	41012466
1102587	93	25505C>A; 25505C>T	g.41016810C>A; g.41016810C>T	g.30512C>A; g.30512C>T	p.R487S; p.R487C	CYP2B6	rs3211371	41016810
778519	105	c.281_283delAGA	g.154535370_154535372delTCT	g.17201_17203delAGA	p.K95del	G6PD	\N	154535370
2406830	67	c.680G>A;c.680G>T	g.154534125C>T;g.154534125C>A	g.18448G>A;g.18448G>T	p.R227Q;p.R227L	G6PD	rs137852328	154534125
778566	105	c.724_729delGGCACT	g.154534076_154534081delAGTGCC	g.18492_18497delGGCACT	p.G242_T243del	G6PD	\N	154534076
778589	105	c.955_988delACCAAAGGGTACCTGGACGACCCC	g.154533015_154533038delGGGGTCGTCCAGGTACCCTTTGGT	g.19535_19569delACCAAAGGGTACCTGGACGACCCC	p.T319_P326del	G6PD	\N	154533015
778617	105	c.1159C>T	g.154532695G>A	g.19878C>T	p.R387C	G6PD	rs137852334	154532695
2406903	67	c.1229G>A;c.1229G>C	g.154532625C>T;g.154532625C>G	g.19948G>A;g.19948G>C	p.G410D;p.G410A	G6PD	rs137852336	154532625
778653	105	c.1380G>C	g.154532265C>G	g.20308G>C	p.E460D	G6PD	\N	154532265
777511	105	12748G>A	g.94775453G>A	g.17773G>A	p.R132Q	CYP2C19	rs72552267	94775453
777520	105	19294T>A	g.94781999T>A	g.24319T>A	splicing defect	CYP2C19	rs72558186	94781999
777529	105	90209A>C	g.94852914A>C	g.95234A>C	p.X491C	CYP2C19	rs55640102	94852914
949529	97	50delGAGTCG; 55_56insGAGTCG	g.48037784GAGTCG[2]; g.48037784GAGTCG[4]	g.5218GAGTCG[2]; g.5218GAGTCG[4]	p.del17_18GV; p.V18_V19insGV	NUDT15	rs746071566	48037784
8102242	1	99G>T	g.48037845G>T	g.5279G>T	p.K33N	NUDT15	rs150241065	48037845
8102245	1	106G>T	g.48037852G>T	g.5286G>T	p.G36C	NUDT15	rs753319151	48037852
777602	105	1A>G	g.94938683A>G	g.5526A>G	p.M1V	CYP2C9	rs114071557	94938683
777611	105	3300G>T	g.94941982G>T	g.8825G>T	p.G98V	CYP2C9	rs762239445	94941982
777618	105	3552G>A; 3552G>T	g.94942234G>A; g.94942234G>T	g.9077G>A; g.9077G>T	p.R125H; p.R125L	CYP2C9	rs72558189	94942234
777643	105	42517G>T	g.94981199G>T	g.48042G>T	p.E326D	CYP2C9	\N	94981199
777655	105	42683C>T	g.94981365C>T	g.48208C>T	p.P382S	CYP2C9	rs2492650213	94981365
777657	105	47360A>G	g.94986042A>G	g.52885A>G	p.I387V	CYP2C9	rs764211126	94986042
3684998	43	c.178G>A; c.178G>T	g.38442361G>A; g.38442361G>T	g.13662G>A; g.13662G>T	p.D60N; p.D60Y	RYR1	rs118192160	38442361
3685013	43	c.528G>T	g.38444252G>T	g.15553G>T	p.E176D	RYR1	\N	38444252
3685030	43	c.1201C>T; c.1201C>A; c.1201C>G	g.38451842C>T; g.38451842C>A; g.38451842C>G	g.23143C>T; g.23143C>A; g.23143C>G	p.R401C; p.R401S; p.R401G	RYR1	rs193922764	38451842
8102343	1	c.1390C>A	g.38452964C>A	g.24265C>A	p.Q464K	RYR1	\N	38452964
8102379	1	c.4055C>G	g.38473666C>G	g.44967C>G	p.A1352G	RYR1	rs112105381	38473666
8102386	1	c.4999C>T	g.38485654C>T	g.56955C>T	p.R1667C	RYR1	rs144157950	38485654
3685098	43	c.6488G>A; c.6488G>C; c.6488G>T	g.38494565G>A; g.38494565G>C; g.38494565G>T	g.65866G>A; g.65866G>C; g.65866G>T	p.R2163H; p.R2163P; p.R2163L	RYR1	rs118192163	38494565
3685143	43	c.7291G>A; c.7291G>T	g.38499984G>A; g.38499984G>T	g.71285G>A; g.71285G>T	p.D2431N; p.D2431Y	RYR1	rs193922810	38499984
8102473	1	c.7625G>A	g.38502517G>A	g.73818G>A	p.S2542N	RYR1	rs1220636855	38502517
3685168	43	c.7879G>C; c.7879G>A	g.38502923G>C; g.38502923G>A	g.74224G>C; g.74224G>A	p.V2627L; p.V2627M	RYR1	rs914804033	38502923
8102500	1	c.9353C>T	g.38512364C>T	g.83665C>T	p.A3118V	RYR1	rs2915960	38512364
3685245	43	c.12700G>C; c.12700G>T	g.38565034G>C; g.38565034G>T	g.136335G>C; g.136335G>T	p.V4234L; p.V4234L	RYR1	rs193922852	38565034
8102562	1	c.13502C>T	g.38566975C>T	g.138276C>T	p.P4501L	RYR1	rs73933023	38566975
3685259	43	c.13994_13995delTCinsCT	g.38572266_38572267delinsCT	g.143567_143568delinsCT	p.L4665P	RYR1	rs193922862	38572266
777927	105	4157A>C	g.42126635T>G	g.9176A>C	p.H478P	CYP2D6	rs766507177	42126635
1103089	93	4135_4136insTGCCCACTG	g.42126658_42126666dup	g.9146_9154dup	p.468_470dupVPT	CYP2D6	rs765776661	42126658
1355509	88	1864_1865insTTTCGCCCCTTTCGCCCC; 1864_1865insTTTCGCCCC	g.42128934AAAGGGGCG[3]; g.42128934_42128942dup	g.6875TTTCGCCCC[3]; g.6875_6883dup	p.174_175insFRPx2; p.174_175insFRP	CYP2D6	rs72549356	42128934
777848	105	1721A>C; 1721A>T	g.42129071T>G; g.42129071T>A	g.6740A>C; g.6740A>T	p.E156A; p.E156V	CYP2D6	rs267608302	42129071
8100710	1	1687G>T	g.42129105C>A	g.6706G>T	p.G145C	CYP2D6	rs1399114415	42129105
779262	105	55402G>A	g.21196976G>A	g.70783G>A	p.R253Q	SLCO1B1	rs11045853	21196976
6237866	15	59099G>A	g.21200673G>A	g.74480G>A	splicing defect	SLCO1B1	rs756393362	21200673
\.


--
-- Data for Name: statistic; Type: TABLE DATA; Schema: cpic; Owner: -
--

COPY cpic.statistic (createdon, stattype, statvalue) FROM stdin;
2025-03-17 09:33:26.107	COUNT_GUIDELINE_PUBLICATIONS	45
2025-03-17 09:33:26.107	COUNT_PAIRS	573
2025-03-17 09:33:26.107	SIZE_DB	1423774511
2025-03-17 09:33:26.107	COUNT_FILES_PUBLISHED	776
2025-03-17 09:33:26.107	COUNT_DB_ROWS	475353
2025-03-17 09:33:26.107	COUNT_GUIDELINES	30
2025-03-17 09:33:26.107	COUNT_DB_TABLES	24
2025-03-17 09:33:26.107	COUNT_DB_DL	105
2025-03-17 09:33:26.107	SIZE_DB_TRANSFER	11252883
2025-03-17 09:33:26.107	COUNT_ALL_RELEASE	30
2025-03-17 09:33:26.107	COUNT_RELEASE	30
2025-07-29 12:48:48.129	COUNT_DB_TABLES	24
2025-07-29 12:48:48.129	COUNT_DB_ROWS	485686
2025-07-29 12:48:48.129	COUNT_FILES_PUBLISHED	776
2025-07-29 12:48:48.129	COUNT_GUIDELINE_PUBLICATIONS	45
2025-07-29 12:48:48.129	COUNT_GUIDELINES	30
2025-07-29 12:48:48.129	SIZE_DB	1436046127
2025-07-29 12:48:48.129	COUNT_PAIRS	573
2025-07-29 12:48:48.129	SIZE_DB_TRANSFER	91577039
2025-07-29 12:48:48.129	COUNT_ALL_RELEASE	71
2025-07-29 12:48:48.129	COUNT_DB_DL	1285
2025-07-29 12:48:48.129	COUNT_RELEASE	64
2025-07-29 12:50:14.329	COUNT_GUIDELINES	30
2025-07-29 12:50:14.329	COUNT_PAIRS	573
2025-07-29 12:50:14.329	COUNT_FILES_PUBLISHED	776
2025-07-29 12:50:14.329	SIZE_DB	1436046127
2025-07-29 12:50:14.329	COUNT_GUIDELINE_PUBLICATIONS	45
2025-07-29 12:50:14.329	COUNT_DB_ROWS	485686
2025-07-29 12:50:14.329	COUNT_DB_TABLES	24
2025-07-29 12:50:14.329	COUNT_DB_DL	1285
2025-07-29 12:50:14.329	SIZE_DB_TRANSFER	91577039
2025-07-29 12:50:14.329	COUNT_ALL_RELEASE	71
2025-07-29 12:50:14.329	COUNT_RELEASE	64
2026-02-06 09:42:04.702	SIZE_DB	1434374959
2026-02-06 09:42:04.702	COUNT_PAIRS	573
2026-02-06 09:42:04.702	COUNT_GUIDELINES	31
2026-02-06 09:42:04.702	COUNT_DB_ROWS	500418
2026-02-06 09:42:04.702	COUNT_DB_TABLES	24
2026-02-06 09:42:04.702	COUNT_FILES_PUBLISHED	783
2026-02-06 09:42:04.702	COUNT_GUIDELINE_PUBLICATIONS	47
2026-02-06 09:42:04.702	SIZE_DB_TRANSFER	91577039
2026-02-06 09:42:04.702	COUNT_DB_DL	1294
2026-02-06 09:42:04.702	COUNT_RELEASE	73
2026-02-06 09:42:04.702	COUNT_ALL_RELEASE	80
\.


--
-- Data for Name: term; Type: TABLE DATA; Schema: cpic; Owner: -
--

COPY cpic.term (id, category, term, functionaldef, geneticdef, loinc, version) FROM stdin;
110037	Allele functional status: all genes	Increased function	Function greater than normal function	N/A	\N	1
110038	Allele functional status: all genes	Normal function	Fully functional/wild-type	N/A	\N	1
110039	Allele functional status: all genes	Decreased function	Function less than normal function	N/A	\N	1
110040	Allele functional status: all genes	No function	Nonfunctional	N/A	\N	1
110041	Allele functional status: all genes	Unknown function	No literature describing function or the allele is novel	N/A	\N	1
110042	Allele functional status: all genes	Uncertain function	Literature supporting function is conflicting or weak	N/A	\N	1
110043	Phenotype: drug-metabolizing enzymes	Ultrarapid metabolizer	Increased enzyme activity compared to rapid metabolizers	Two increased function alleles, or more than 2 normal function alleles	\N	1
110044	Phenotype: drug-metabolizing enzymes	Rapid metabolizer	Increased enzyme activity compared to normal metabolizers but less than ultrarapid metabolizers	Combinations of normal function and increased function alleles	\N	1
110045	Phenotype: drug-metabolizing enzymes	Normal metabolizer	Fully functional enzyme activity	Combinations of normal function and decreased function alleles	\N	1
110046	Phenotype: drug-metabolizing enzymes	Intermediate metabolizer	Decreased enzyme activity (activity between normal and poor metabolizer)	Combinations of normal function, decreased function, and/or no function alleles	\N	1
110047	Phenotype: drug-metabolizing enzymes	Poor metabolizer	Little to no enzyme activity	Combination of no function alleles and/ or decreased function alleles	\N	1
110048	Phenotype: transporters	Increased function	Increased transporter function compared to normal function. 	One or more increased function alleles	\N	1
110049	Phenotype: transporters	Normal function	Fully functional transporter function 	Combinations of normal function and/ or decreased function alleles	\N	1
110050	Phenotype: transporters	Decreased function	Decreased transporter function (function between normal and poor function) 	Combinations of normal function, decreased function, and/or no function alleles	\N	1
110051	Phenotype: transporters	Poor function	Little to no transporter function	Combination of no function alleles and/ or decreased function alleles	\N	1
110052	Phenotype: high-risk genotype status	Positive	Detection of high-risk allele	Homozygous or heterozygous for high-risk allele	\N	1
110053	Phenotype: high-risk genotype status	Negative	High-risk allele not detected	No copies of high-risk allele	\N	1
\.


--
-- Data for Name: test_alert; Type: TABLE DATA; Schema: cpic; Owner: -
--

COPY cpic.test_alert (id, population, cdscontext, genes, phenotype, activityscore, allelestatus, lookupkey, drugid, alerttext, version) FROM stdin;
8224275	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224276	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224277	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224278	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224279	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224280	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224281	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224282	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224283	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224284	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224486	general	No CDS	{UGT1A1}	{"UGT1A1": "Indeterminate"}	{}	{}	{"UGT1A1": "Indeterminate"}	RxNorm:343047	{n/a}	1
8224285	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224286	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224287	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224288	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224289	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224290	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224291	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224292	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224293	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224722	general	No CDS	{CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{}	{}	{"CYP2C19": "Normal Metabolizer"}	RxNorm:32968	{n/a}	1
8225888	aspirin <1g	No CDS	{G6PD}	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	RxNorm:1191	{n/a}	1
8224294	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224295	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224296	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224297	general	Pre-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2C19 genotype may be important for amitriptyline dosing and use. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent or dose may be recommended. Please consult a clinical pharmacist for more information."}	1
8224298	general	Pre-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "No Result"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. Neither a CYP2D6 nor CYP2C19 genotype appears to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224299	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a likely CYP2C19 poor metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224300	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224301	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224302	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{n/a}	1
8224303	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224304	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224305	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224306	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224307	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224308	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224309	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224310	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224311	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224312	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Indeterminate"}	RxNorm:704	{n/a}	1
8224313	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224314	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224315	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224316	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224317	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224318	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224319	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224320	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224321	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224322	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224323	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a likely CYP2C19 intermediate metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224324	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224325	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8225533	general	No CDS	{CYP2B6,CYP2C19}	{"CYP2B6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}	{}	{}	{"CYP2B6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}	RxNorm:36437	{n/a}	1
8224326	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224327	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224328	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{n/a}	1
8224329	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{n/a}	1
8224330	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{n/a}	1
8224331	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{n/a}	1
8224332	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{n/a}	1
8224333	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224334	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224335	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224336	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224337	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224338	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224350	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information."}	1
8224339	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224340	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224341	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224342	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224343	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224344	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 intermediate metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224345	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224346	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224347	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224348	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.Please consult a clinical pharmacist for more information."}	1
8224349	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224351	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information."}	1
8224352	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information."}	1
8224353	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information."}	1
8224354	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information."}	1
8224355	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224356	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224357	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224358	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224359	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224360	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224361	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224487	general	Pre-test	{SLCO1B1}	{"SLCO1B1": "No Result"}	{}	{}	{"SLCO1B1": "No Result"}	RxNorm:83367	{"SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information."}	1
8224362	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224363	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224364	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224365	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224366	general	Pre-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Indeterminate"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. CYP2D6 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224367	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224368	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224369	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224370	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224371	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224436	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224372	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224373	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224374	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224375	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224376	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224377	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224378	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224379	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224380	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224381	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224488	general	No CDS	{SLCO1B1}	{"SLCO1B1": "Increased Function"}	{}	{}	{"SLCO1B1": "Increased Function"}	RxNorm:83367	{n/a}	1
8224382	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224383	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224384	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224385	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{n/a}	1
8224386	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224387	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224388	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224389	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224390	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 ultarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224391	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 ultarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2D6 genotype does not appear to have been ordered for this patient. CYP2D6 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224392	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224393	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224394	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224395	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{n/a}	1
8224396	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{n/a}	1
8224397	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224398	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224399	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224400	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224401	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224402	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224403	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224489	general	No CDS	{SLCO1B1}	{"SLCO1B1": "Normal Function"}	{}	{}	{"SLCO1B1": "Normal Function"}	RxNorm:83367	{n/a}	1
8225889	aspirin <1g	No CDS	{G6PD}	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	RxNorm:1191	{n/a}	1
8224404	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224405	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224406	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{n/a}	1
8224407	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224408	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224409	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224410	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224411	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224412	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224413	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224414	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8226300	general	No CDS	{G6PD}	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	RxNorm:10178	{n/a}	1
8224415	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224416	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224417	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Rapid Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2D6 genotype does not appear to have been ordered for this patient. CYP2D6 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224418	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 poor metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224419	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224420	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224421	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224422	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224423	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224424	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8226301	general	No CDS	{G6PD}	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	RxNorm:10178	{n/a}	1
8224425	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224426	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{n/a}	1
8224427	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224428	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224429	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224430	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224431	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224432	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224433	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224434	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224435	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8225328	non-H.pylori_erosive	Pre-test	{CYP2C19}	{"CYP2C19": "No Result"}	{}	{}	{"CYP2C19": "No Result"}	RxNorm:17128	{"CYP2C19 genotype may be important for this proton pump inhibitor's dosing. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information."}	1
8224437	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224438	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224439	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224440	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Poor Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224441	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, this patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224442	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments."}	1
8224443	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments."}	1
8224444	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments."}	1
8224445	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments."}	1
8224446	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{n/a}	1
8224447	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{n/a}	1
8224471	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224448	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224449	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224450	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224451	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224452	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224453	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224454	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224455	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224456	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224457	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224458	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224459	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224460	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Normal Metabolizer"}	RxNorm:704	{n/a}	1
8224461	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 intermediate metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224462	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224463	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224464	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224465	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224466	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{n/a}	1
8224467	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{n/a}	1
8224468	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{n/a}	1
8224469	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224470	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224472	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224473	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224474	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224475	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224476	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224477	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224478	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224479	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224480	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 intermediate metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224481	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:704	{n/a}	1
8224482	general	Pre-test	{UGT1A1}	{"UGT1A1": "No Result"}	{}	{}	{"UGT1A1": "No Result"}	RxNorm:343047	{"UGT1A1 genetic status may be predictive of cosmetic jaundice with this medication. A UGT1A1 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information."}	1
8224483	general	No CDS	{UGT1A1}	{"UGT1A1": "Normal Metabolizer"}	{}	{}	{"UGT1A1": "Normal Metabolizer"}	RxNorm:343047	{n/a}	1
8224484	general	No CDS	{UGT1A1}	{"UGT1A1": "Intermediate Metabolizer"}	{}	{}	{"UGT1A1": "Intermediate Metabolizer"}	RxNorm:343047	{n/a}	1
8224485	general	Post-test	{UGT1A1}	{"UGT1A1": "Poor Metabolizer"}	{}	{}	{"UGT1A1": "Poor Metabolizer"}	RxNorm:343047	{"This patient is predicted to be a UGT1A1 poor metabolizer and may be at an increased risk of developing jaundice with atazanavir use. Consider an alternative agent particularly if jaundice would be of concern to the patient. Please consult a clinical pharmacist for more information."}	1
8224490	general	Post-test	{SLCO1B1}	{"SLCO1B1": "Decreased Function"}	{}	{}	{"SLCO1B1": "Decreased Function"}	RxNorm:83367	{"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."}	1
8224491	general	Post-test	{SLCO1B1}	{"SLCO1B1": "Possible Decreased Function"}	{}	{}	{"SLCO1B1": "Possible Decreased Function"}	RxNorm:83367	{"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."}	1
8224492	general	Post-test	{SLCO1B1}	{"SLCO1B1": "Poor Function"}	{}	{}	{"SLCO1B1": "Poor Function"}	RxNorm:83367	{"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."}	1
8224493	general	No CDS	{SLCO1B1}	{"SLCO1B1": "Indeterminate"}	{}	{}	{"SLCO1B1": "Indeterminate"}	RxNorm:83367	{n/a}	1
8224494	general	Pre-test	{HLA-B,HLA-A}	{}	{}	{"HLA-A": "No *31:01 result on file", "HLA-B": "No *15:02 result on file"}	{"HLA-A": "No *31:01 result on file", "HLA-B": "No *15:02 result on file"}	RxNorm:2002	{"HLA-B*15:02 and HLA-A*31:01 genetic status may be predictive of a severe cutaneous adverse reaction to carbamazepine. Neither a HLA-B*15:02 nor HLA-A*31:01 genotype appears to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224495	general	Post-test	{HLA-B,HLA-A}	{}	{}	{"HLA-A": "*31:01 positive", "HLA-B": "No *15:02 result on file"}	{"HLA-A": "*31:01 positive", "HLA-B": "No *15:02 result on file"}	RxNorm:2002	{"HLA-B*15:02 and HLA-A*31:01 genetic status may be predictive of a severe cutaneous adverse reaction to carbamazepine. This patient is HLA-A*31:01 positive and may be at an increased risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and maculopapular exanthema (MPE). If the patient is carbamazepine-naive and alternative agents are available, do not use carbamazepine. If the patient is carbamazepine-naïve and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction. The latency period for cutaneous adverse drug reactions is short (< 8 weeks); therefore, if the patient has previously used carbamazepine for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine. A HLA-B*15:02 genotype does not appear to have been ordered for this patient. HLA-B*15:02 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224496	general	Pre-test	{HLA-B,HLA-A}	{}	{}	{"HLA-A": "*31:01 negative", "HLA-B": "No *15:02 result on file"}	{"HLA-A": "*31:01 negative", "HLA-B": "No *15:02 result on file"}	RxNorm:2002	{"HLA-B*15:02 and HLA-A*31:01 genetic status may be predictive of a severe cutaneous adverse reaction to carbamazepine. This patient is HLA-A*31:01 negative. There is no reason to alter carbamazepine therapy based on the HLA-A*31:01 result. Because a HLA-B*15:02 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224497	general	Post-test	{HLA-B,HLA-A}	{}	{}	{"HLA-A": "No *31:01 result on file", "HLA-B": "*15:02 positive"}	{"HLA-A": "No *31:01 result on file", "HLA-B": "*15:02 positive"}	RxNorm:2002	{"HLA-B*15:02 and HLA-A*31:01 genetic status may be predictive of a severe cutaneous adverse reaction to carbamazepine. This patient is HLA-B*15:02 positive and may be at an increased risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). If the patient is carbamazepine-naive and alternative agents are available, do not use carbamazepine. The latency period for SJS/TEN is short (< 8 weeks); therefore, if the patient has previously used carbamazepine for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine. A HLA-A*31:01 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information."}	1
8224498	general	Post-test	{HLA-B,HLA-A}	{}	{}	{"HLA-A": "*31:01 positive", "HLA-B": "*15:02 positive"}	{"HLA-A": "*31:01 positive", "HLA-B": "*15:02 positive"}	RxNorm:2002	{"HLA-B*15:02 and HLA-A*31:01 genetic status may be predictive of a severe cutaneous adverse reaction to carbamazepine. This patient is HLA-B*15:02 positive and HLA-A*31:01 positive and may be at an increased risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and maculopapular exanthema (MPE). If the patient is carbamazepine-naive and alternative agents are available, do not use carbamazepine. The latency period for cutaneous adverse drug reactions is short (< 8 weeks); therefore, if the patient has previously used carbamazepine for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine. Please consult a clinical pharmacist for more information."}	1
8224499	general	Post-test	{HLA-B,HLA-A}	{}	{}	{"HLA-A": "*31:01 negative", "HLA-B": "*15:02 positive"}	{"HLA-A": "*31:01 negative", "HLA-B": "*15:02 positive"}	RxNorm:2002	{"HLA-B*15:02 and HLA-A*31:01 genetic status may be predictive of a severe cutaneous adverse reaction to carbamazepine. This patient is HLA-B*15:02 positive and HLA-A*31:01 negative. Based on the HLA-B*15:02 result, the patient may be at an increased risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). If the patient is carbamazepine-naive and alternative agents are available, do not use carbamazepine. The latency period for cutaneous adverse drug reactions is short (< 8 weeks); therefore, if the patient has previously used carbamazepine for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine. Please consult a clinical pharmacist for more information."}	1
8224500	general	Pre-test	{HLA-B,HLA-A}	{}	{}	{"HLA-A": "No *31:01 result on file", "HLA-B": "*15:02 negative"}	{"HLA-A": "No *31:01 result on file", "HLA-B": "*15:02 negative"}	RxNorm:2002	{"HLA-B*15:02 and HLA-A*31:01 genetic status may be predictive of a severe cutaneous adverse reaction to carbamazepine. This patient is HLA-B*15:02 negative. There is no reason to alter carbamazepine therapy based on the HLA-B*15:02 result. Because a HLA-A*31:01 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224501	general	Post-test	{HLA-B,HLA-A}	{}	{}	{"HLA-A": "*31:01 positive", "HLA-B": "*15:02 negative"}	{"HLA-A": "*31:01 positive", "HLA-B": "*15:02 negative"}	RxNorm:2002	{"HLA-B*15:02 and HLA-A*31:01 genetic status may be predictive of a severe cutaneous adverse reaction to carbamazepine. This patient is HLA-B*15:02 negative and HLA-A*31:01 positive. Based on the HLA-A*31:01 result, the patient may be at an increased risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and maculopapular exanthema (MPE). If the patient is carbamazepine-naive and alternative agents are available, do not use carbamazepine. If the patient is carbamazepine-naïve and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction. The latency period for cutaneous adverse drug reactions is short (< 8 weeks); therefore, if the patient has previously used carbamazepine for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine. Please consult a clinical pharmacist for more information."}	1
8224502	general	No CDS	{HLA-B,HLA-A}	{}	{}	{"HLA-A": "*31:01 negative", "HLA-B": "*15:02 negative"}	{"HLA-A": "*31:01 negative", "HLA-B": "*15:02 negative"}	RxNorm:2002	{n/a}	1
8224503	general	Post-test	{CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{}	{}	{"CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2556	{"Based on the genotype result, this patient is predicted to be a CYP2C19 ultrarapid metabolizer and is at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram is clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose. Please consult a clinical pharmacist for more information."}	1
8224504	general	Pre-test	{CYP2C19}	{"CYP2C19": "No Result"}	{}	{}	{"CYP2C19": "No Result"}	RxNorm:2556	{"CYP2C19 genotype may be important for the use of citalopram. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information."}	1
8224505	general	Post-test	{CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{}	{}	{"CYP2C19": "Rapid Metabolizer"}	RxNorm:2556	{"Based on the genotype result, this patient is predicted to be a CYP2C19 rapid metabolizer and may be at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Initiate therapy with recommended starting dose. If patient does not adequately respond, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. Please consult a clinical pharmacist for more information."}	1
8224506	general	No CDS	{CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{}	{}	{"CYP2C19": "Normal Metabolizer"}	RxNorm:2556	{n/a}	1
8224507	general	Post-test	{CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{}	{}	{"CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2556	{"Based on the genotype result, this patient is predicted to be a likely CYP2C19 intermediate metabolizer and is at risk for higher plasma concentrations and increased probability of side effects with standard dosing. Initiate therapy with recommended starting dose, but consider a slower titration schedule and lower maintenance dose. Please consult a clinical pharmacist for more information."}	1
8224508	general	Post-test	{CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{}	{}	{"CYP2C19": "Intermediate Metabolizer"}	RxNorm:2556	{"Based on the genotype result, this patient is predicted to be a CYP2C19 intermediate metabolizer and is at risk for higher plasma concentrations and increased probability of side effects with standard dosing. Initiate therapy with recommended starting dose, but consider a slower titration schedule and lower maintenance dose. Please consult a clinical pharmacist for more information."}	1
8224509	general	Post-test	{CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{}	{}	{"CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2556	{"Based on the genotype result, this patient is predicted to be a likely CYP2C19 poor metabolizer and is at risk for higher plasma concentrations and increased probability of side effects with standard dosing. Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram is clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose. Please consult a clinical pharmacist for more information."}	1
8224510	general	Post-test	{CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{}	{}	{"CYP2C19": "Poor Metabolizer"}	RxNorm:2556	{"Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer and is at risk for higher plasma concentrations and increased probability of side effects with standard dosing. Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram is clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose. Please consult a clinical pharmacist for more information."}	1
8224511	general	No CDS	{CYP2C19}	{"CYP2C19": "Indeterminate"}	{}	{}	{"CYP2C19": "Indeterminate"}	RxNorm:2556	{n/a}	1
8224512	general	Pre-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2C19 genotype may be important for clomipramine dosing and use. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent or dose may be recommended. Please consult a clinical pharmacist for more information."}	1
8226302	general	No CDS	{G6PD}	{"G6PD": "No Result"}	{}	{}	{"G6PD": "No Result"}	RxNorm:10831	{n/a}	1
8224513	general	Pre-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. Neither a CYP2D6 nor CYP2C19 genotype appears to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224514	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224515	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224516	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224517	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224518	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224519	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224520	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224521	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224737	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224522	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224523	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224524	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224525	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{n/a}	1
8224526	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{n/a}	1
8224527	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224528	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224529	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224530	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224531	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224532	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224820	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{n/a}	1
8226303	general	No CDS	{G6PD}	{"G6PD": "Normal"}	{}	{}	{"G6PD": "Normal"}	RxNorm:10831	{n/a}	1
8224533	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224534	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224535	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224536	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "No Result"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "No Result"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224537	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224538	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224539	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224540	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224541	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224542	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224543	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224544	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224545	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information."}	1
8224546	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224547	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224548	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224549	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224550	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224551	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224552	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224563	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224553	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224554	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224555	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224556	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224557	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224558	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224559	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224560	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Likely Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a likely CYP2C19 poor metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224561	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 intermediate metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224562	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{n/a}	1
8224576	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{n/a}	1
8226304	general	No CDS	{G6PD}	{"G6PD": "Deficient"}	{}	{}	{"G6PD": "Deficient"}	RxNorm:10831	{n/a}	1
8224564	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224565	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224566	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224567	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224568	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224569	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224570	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224571	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224572	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224573	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224574	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{n/a}	1
8224575	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{n/a}	1
8226426	general	No CDS	{CYP2D6}	{}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5"}	RxNorm:27392	{n/a}	1
8224577	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224578	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224579	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224580	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224581	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a likely CYP2C19 intermediate metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224582	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Indeterminate"}	RxNorm:2597	{n/a}	1
8224583	general	Pre-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. CYP2D6 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224584	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224585	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224586	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224587	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8226427	general	No CDS	{CYP2D6}	{}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25"}	RxNorm:27392	{n/a}	1
8224588	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224589	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224590	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224591	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224592	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224593	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224594	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224595	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information."}	1
8224596	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information."}	1
8224597	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information."}	1
8224598	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information."}	1
8225345	general	Pre-test	{RYR1,CACNA1S}	{"RYR1": "No Result", "CACNA1S": "No Result"}	{}	{}	{"RYR1": "No Result", "CACNA1S": "No Result"}	RxNorm:6857	{"Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use."}	1
8224599	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224600	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.Please consult a clinical pharmacist for more information."}	1
8224601	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224602	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224603	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Indeterminate"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Indeterminate"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224604	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 ultarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224605	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 ultarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2D6 genotype does not appear to have been ordered for this patient. CYP2D6 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8224606	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224607	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224608	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8225346	general	No CDS	{RYR1,CACNA1S}	{"RYR1": "Uncertain Susceptibility", "CACNA1S": "Uncertain Susceptibility"}	{}	{}	{"RYR1": "Uncertain Susceptibility", "CACNA1S": "Uncertain Susceptibility"}	RxNorm:6857	{n/a}	1
8226428	general	No CDS	{CYP2D6}	{}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0"}	RxNorm:27392	{n/a}	1
8224609	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224610	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224611	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224612	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224613	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224614	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224615	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224616	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224617	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224618	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8226429	general	No CDS	{CYP2D6}	{}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a"}	RxNorm:27392	{n/a}	1
8224619	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224620	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224621	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224622	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224623	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224624	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224625	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224626	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224627	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224628	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2D6 genotype does not appear to have been ordered for this patient. CYP2D6 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
8226430	general	No CDS	{CYP2D6}	{}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0"}	RxNorm:39786	{n/a}	1
8224629	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224630	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224631	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224632	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224633	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224634	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224635	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224636	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224637	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224638	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8225347	general	Pre-test	{CYP2D6}	{}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result"}	RxNorm:7531	{"CYP2D6 genetic status may be important for nortriptyline dosing and use. A CYP2D6 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224639	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224640	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224641	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224642	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224643	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224644	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224645	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224646	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224647	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224648	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8226431	general	No CDS	{CYP2D6}	{}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75"}	RxNorm:39786	{n/a}	1
8224649	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224650	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224651	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224652	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224653	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224654	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224655	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224656	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224657	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224658	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224659	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224660	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224661	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224662	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224663	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224664	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224665	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224666	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224667	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224668	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224669	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8226432	general	No CDS	{CYP2D6}	{}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5"}	RxNorm:39786	{n/a}	1
8224670	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224671	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224672	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 poor metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224673	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224674	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{n/a}	1
8224675	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224676	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224677	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224678	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224679	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224693	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments."}	1
8224680	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224681	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224682	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224683	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224684	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224685	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224686	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{n/a}	1
8224687	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{n/a}	1
8224688	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{n/a}	1
8224689	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{n/a}	1
8224690	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{n/a}	1
8224691	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments."}	1
8224692	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments."}	1
8224719	general	Pre-test	{CYP2C19}	{"CYP2C19": "No Result"}	{}	{}	{"CYP2C19": "No Result"}	RxNorm:32968	{"The patient's CYP2C19 genotype may be important for choice of antiplatelet therapy. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information."}	1
8224694	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments."}	1
8224695	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, this patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224696	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 intermediate metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224697	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{n/a}	1
8224698	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224699	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224700	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224701	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224702	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224703	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224704	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224720	general	No CDS	{CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{}	{}	{"CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:32968	{n/a}	1
8224721	general	No CDS	{CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{}	{}	{"CYP2C19": "Rapid Metabolizer"}	RxNorm:32968	{n/a}	1
8224705	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224706	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224707	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224708	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224709	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{n/a}	1
8224710	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{n/a}	1
8224711	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{n/a}	1
8224712	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{n/a}	1
8224713	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{n/a}	1
8224714	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224715	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224716	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224717	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224718	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:2597	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 intermediate metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224723	general	Post-test	{CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{}	{}	{"CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:32968	{"Based on the genotype result, this patient is predicted to be a CYP2C19 likely intermediate metabolizer. Avoid standard dose clopidogrel (75 mg) if possible due to the risk of therapeutic failure in patients that had a recent acute coronary syndrome and/or a percutaneous coronary intervention, or a neurovascular indication for clopidogrel. Consider use of an alternative antiplatelet agent at standard dose if no contraindication. Prasugrel is contraindicated in patients with a history of transient ischemic attack or stroke. Please consult a clinical pharmacist for more information."}	1
8224724	general	Post-test	{CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{}	{}	{"CYP2C19": "Intermediate Metabolizer"}	RxNorm:32968	{"Based on the genotype result, this patient is predicted to be a CYP2C19 intermediate metabolizer. Avoid standard dose clopidogrel (75 mg) if possible due to the risk of therapeutic failure in patients that had a recent acute coronary syndrome and/or a percutaneous coronary intervention, or a neurovascular indication for clopidogrel. Consider use of an alternative antiplatelet agent at standard dose if no contraindication. Prasugrel is contraindicated in patients with a history of transient ischemic attack or stroke. Please consult a clinical pharmacist for more information."}	1
8224725	general	Post-test	{CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{}	{}	{"CYP2C19": "Likely Poor Metabolizer"}	RxNorm:32968	{"Based on the genotype result, this patient is predicted to be a CYP2C19 likely poor metabolizer. Avoid clopidogrel if possible due to the risk of therapeutic failure. Use an alternative antiplatelet agent at standard dose if no contraindication. Prasugrel is contraindicated in patients with a history of transient ischemic attack or stroke. Please consult a clinical pharmacist for more information."}	1
8224726	general	Post-test	{CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{}	{}	{"CYP2C19": "Poor Metabolizer"}	RxNorm:32968	{"Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer. Avoid clopidogrel if possible due to the risk of therapeutic failure. Use an alternative antiplatelet agent at standard dose if no contraindication. Prasugrel is contraindicated in patients with a history of transient ischemic attack or stroke. Please consult a clinical pharmacist for more information."}	1
8224727	general	No CDS	{CYP2C19}	{"CYP2C19": "Indeterminate"}	{}	{}	{"CYP2C19": "Indeterminate"}	RxNorm:32968	{n/a}	1
8224728	general	Post-test	{RYR1,CACNA1S}	{"RYR1": "Uncertain Susceptibility", "CACNA1S": "Malignant Hyperthermia Susceptibility"}	{}	{}	{"RYR1": "Uncertain Susceptibility", "CACNA1S": "Malignant Hyperthermia Susceptibility"}	RxNorm:27340	{"Based on genotype, this patient is predicted to be malignant hyperthermia susceptible. Halogenated volatile anesthetics or depolarizing muscle relaxants are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available, effective, and safe in patients with MHS. Please consult an anesthesiologist or clinical pharmacist for more information."}	1
8224729	general	Post-test	{RYR1,CACNA1S}	{"RYR1": "Malignant Hyperthermia Susceptibility", "CACNA1S": "Uncertain Susceptibility"}	{}	{}	{"RYR1": "Malignant Hyperthermia Susceptibility", "CACNA1S": "Uncertain Susceptibility"}	RxNorm:27340	{"Based on genotype, this patient is predicted to be malignant hyperthermia susceptible. Halogenated volatile anesthetics or depolarizing muscle relaxants are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available, effective, and safe in patients with MHS. Please consult an anesthesiologist or clinical pharmacist for more information."}	1
8224730	general	Pre-test	{RYR1,CACNA1S}	{"RYR1": "Uncertain Susceptibility", "CACNA1S": "No Result"}	{}	{}	{"RYR1": "Uncertain Susceptibility", "CACNA1S": "No Result"}	RxNorm:27340	{"Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use."}	1
8224731	general	Pre-test	{RYR1,CACNA1S}	{"RYR1": "No Result", "CACNA1S": "Uncertain Susceptibility"}	{}	{}	{"RYR1": "No Result", "CACNA1S": "Uncertain Susceptibility"}	RxNorm:27340	{"Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use."}	1
8224732	general	Pre-test	{RYR1,CACNA1S}	{"RYR1": "No Result", "CACNA1S": "No Result"}	{}	{}	{"RYR1": "No Result", "CACNA1S": "No Result"}	RxNorm:27340	{"Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use."}	1
8224733	general	No CDS	{RYR1,CACNA1S}	{"RYR1": "Uncertain Susceptibility", "CACNA1S": "Uncertain Susceptibility"}	{}	{}	{"RYR1": "Uncertain Susceptibility", "CACNA1S": "Uncertain Susceptibility"}	RxNorm:27340	{n/a}	1
8224734	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 intermediate metabolizer and may experience higher than expected plasma concentrations of desipramine resulting in an increased the probability of adverse reactions. Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224735	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224736	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224738	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224739	general	No CDS	{CYP2D6}	{}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25"}	RxNorm:3247	{n/a}	1
8224740	general	No CDS	{CYP2D6}	{}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0"}	RxNorm:3247	{n/a}	1
8224741	general	No CDS	{CYP2D6}	{}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75"}	RxNorm:3247	{n/a}	1
8224742	general	No CDS	{CYP2D6}	{}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5"}	RxNorm:3247	{n/a}	1
8224743	general	No CDS	{CYP2D6}	{}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25"}	RxNorm:3247	{n/a}	1
8224744	general	Pre-test	{CYP2D6}	{}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result"}	RxNorm:3247	{"CYP2D6 genetic status may be important for desipramine dosing and use. A CYP2D6 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224745	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224746	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224747	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224748	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224749	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224750	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224751	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224752	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 intermediate metabolizer and may experience higher than expected plasma concentrations of desipramine resulting in an increased the probability of adverse reactions. Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224753	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 intermediate metabolizer and may experience higher than expected plasma concentrations of desipramine resulting in an increased the probability of adverse reactions. Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224754	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 intermediate metabolizer and may experience higher than expected plasma concentrations of desipramine resulting in an increased the probability of adverse reactions. Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224755	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0"}	RxNorm:3247	{"Based on the genotype result, this patient is predicted to be a CYP2D6 poor metabolizer and may experience higher than expected plasma concentrations of desipramine resulting in an increased the probability of adverse reactions. Consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224756	general	No CDS	{CYP2D6}	{}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a"}	RxNorm:3247	{n/a}	1
8224757	H.pylori_erosive eso	Post-test	{CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{}	{}	{"CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:816346	{"Based on the genotype result, this patient is predicted to be a CYP2C19 ultrarapid metabolizer and is at risk for decreased plasma concentrations and therapeutic failure with standard dosing. Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy. Please consult a clinical pharmacist for more information."}	1
8224758	H.pylori_erosive eso	Post-test	{CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{}	{}	{"CYP2C19": "Rapid Metabolizer"}	RxNorm:816346	{"Based on the genotype result, this patient is predicted to be a CYP2C19 rapid metabolizer. The patient may be at risk for therapeutic failure at standard doses. Consider increasing the dose by 50-100%. Daily dose may be given in divided doses. Monitor for efficacy. Please consult a clinical pharmacist for more information."}	1
8224759	H.pylori_erosive eso	Pre-test	{CYP2C19}	{"CYP2C19": "No Result"}	{}	{}	{"CYP2C19": "No Result"}	RxNorm:816346	{"CYP2C19 genotype may be important for this proton pump inhibitor's dosing. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information."}	1
8224760	H.pylori_erosive eso	Post-test	{CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{}	{}	{"CYP2C19": "Normal Metabolizer"}	RxNorm:816346	{"Based on the genotype result, this patient is predicted to be a CYP2C19 normal metabolizer. The patient may be at risk for therapeutic failure at standard doses. Consider increasing the dose by 50-100%. Daily dose may be given in divided doses. Monitor for efficacy. Please consult a clinical pharmacist for more information."}	1
8224761	H.pylori_erosive eso	Post-test	{CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{}	{}	{"CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:816346	{"Based on the genotype result, this patient is predicted to be a CYP2C19 likely intermediate metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information."}	1
8224762	H.pylori_erosive eso	Post-test	{CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{}	{}	{"CYP2C19": "Intermediate Metabolizer"}	RxNorm:816346	{"Based on the genotype result, this patient is predicted to be a CYP2C19 intermediate metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information."}	1
8224763	H.pylori_erosive eso	Post-test	{CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{}	{}	{"CYP2C19": "Likely Poor Metabolizer"}	RxNorm:816346	{"Based on the genotype result, this patient is predicted to be a CYP2C19 likely poor metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information."}	1
8224764	H.pylori_erosive eso	Post-test	{CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{}	{}	{"CYP2C19": "Poor Metabolizer"}	RxNorm:816346	{"Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information."}	1
8224765	H.pylori_erosive eso	No CDS	{CYP2C19}	{"CYP2C19": "Indeterminate"}	{}	{}	{"CYP2C19": "Indeterminate"}	RxNorm:816346	{n/a}	1
8224766	non-H.pylori_erosive	Pre-test	{CYP2C19}	{"CYP2C19": "No Result"}	{}	{}	{"CYP2C19": "No Result"}	RxNorm:816346	{"CYP2C19 genotype may be important for this proton pump inhibitor's dosing. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information."}	1
8224767	non-H.pylori_erosive	Post-test	{CYP2C19}	{"CYP2C19": "Ultrarapid Metabolizer"}	{}	{}	{"CYP2C19": "Ultrarapid Metabolizer"}	RxNorm:816346	{"Based on the genotype result, this patient is predicted to be a CYP2C19 ultrarapid metabolizer and is at risk for decreased plasma concentrations and therapeutic failure with standard dosing. Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy. Please consult a clinical pharmacist for more information."}	1
8224768	non-H.pylori_erosive	No CDS	{CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{}	{}	{"CYP2C19": "Rapid Metabolizer"}	RxNorm:816346	{n/a}	1
8224769	non-H.pylori_erosive	No CDS	{CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{}	{}	{"CYP2C19": "Normal Metabolizer"}	RxNorm:816346	{n/a}	1
8224770	non-H.pylori_erosive	Post-test	{CYP2C19}	{"CYP2C19": "Likely Intermediate Metabolizer"}	{}	{}	{"CYP2C19": "Likely Intermediate Metabolizer"}	RxNorm:816346	{"Based on the genotype result, this patient is predicted to be a CYP2C19 likely intermediate metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information."}	1
8226433	general	No CDS	{CYP2D6}	{}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25"}	RxNorm:39786	{n/a}	1
8224771	non-H.pylori_erosive	Post-test	{CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{}	{}	{"CYP2C19": "Intermediate Metabolizer"}	RxNorm:816346	{"Based on the genotype result, this patient is predicted to be a CYP2C19 intermediate metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information."}	1
8224772	non-H.pylori_erosive	Post-test	{CYP2C19}	{"CYP2C19": "Likely Poor Metabolizer"}	{}	{}	{"CYP2C19": "Likely Poor Metabolizer"}	RxNorm:816346	{"Based on the genotype result, this patient is predicted to be a CYP2C19 likely poor metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information."}	1
8224773	non-H.pylori_erosive	Post-test	{CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{}	{}	{"CYP2C19": "Poor Metabolizer"}	RxNorm:816346	{"Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information."}	1
8224774	non-H.pylori_erosive	No CDS	{CYP2C19}	{"CYP2C19": "Indeterminate"}	{}	{}	{"CYP2C19": "Indeterminate"}	RxNorm:816346	{n/a}	1
8224775	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{n/a}	1
8224776	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{n/a}	1
8224777	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224778	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224779	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224780	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224781	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{n/a}	1
8224782	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{n/a}	1
8224783	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{n/a}	1
8224784	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 intermediate metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8225348	general	Post-test	{CYP2D6}	{}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0"}	RxNorm:7531	{"Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If nortriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224785	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224786	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224787	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224788	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224789	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224790	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224791	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224792	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224793	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224794	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224795	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224796	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{n/a}	1
8224797	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Intermediate Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 intermediate metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224798	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments."}	1
8224799	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments."}	1
8224800	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments."}	1
8224801	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments."}	1
8224802	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{n/a}	1
8224803	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{n/a}	1
8224804	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{n/a}	1
8224805	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{n/a}	1
8224806	general	No CDS	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{n/a}	1
8224807	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224808	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, this patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224809	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224821	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224810	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224811	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224812	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224813	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224814	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224815	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224816	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224817	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224818	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224819	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Normal Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224822	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224823	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224824	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224825	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224826	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224827	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224828	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224829	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224830	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224831	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 poor metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224832	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224833	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224834	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224835	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224836	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224837	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224838	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224839	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224840	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224841	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224842	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224994	general	No CDS	{RYR1,CACNA1S}	{"RYR1": "Uncertain Susceptibility", "CACNA1S": "Uncertain Susceptibility"}	{}	{}	{"RYR1": "Uncertain Susceptibility", "CACNA1S": "Uncertain Susceptibility"}	RxNorm:3920	{n/a}	1
8224843	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Poor Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information."}	1
8224844	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.0"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224845	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.75"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224846	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224847	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.25"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224848	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.25"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224849	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.0"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224850	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.75"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224851	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.5"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224852	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.25"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224853	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.0"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224854	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥6.0"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224855	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥5.0"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224856	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.75"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224857	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥4.0"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224858	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.5"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224859	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.25"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224860	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.0"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224861	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "4.0"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224862	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.75"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224995	general	Pre-test	{CYP2C19}	{"CYP2C19": "No Result"}	{}	{}	{"CYP2C19": "No Result"}	RxNorm:321988	{"CYP2C19 genotype may be important for the use of escitalopram. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information."}	1
8224863	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "3.0"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224864	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.5"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224865	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information."}	1
8224866	general	Post-test	{CYP2D6,CYP2C19}	{"CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "No Result"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Rapid Metabolizer"}	RxNorm:3638	{"CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2D6 genotype does not appear to have been ordered for this patient. CYP2D6 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information."}	1
